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Introduction 

IntroduGtion 
P .. " . AI\ALYSIS AGITANS HAS existed in the world since ancient times. Its fIrst clear , ..• description is found in the old Indian medical system Ayurveda described from ! 4500 to 1000 Be under the name Kampavata. 1 Herbal preparations like mucuna 
prurlens, commonly kno\vn as velvet bean or cowitch and containing levodopa, were 
used in the treatment of Kampavata.2 At present tllis entity is labeled Parkinson's dis-
ease (PO) which has been described by James Parkinson in his monograph "Shaking 
Palsy" in 1817.3 He defined PD as "IIiPolm/M1)' frelJllllotIJ lJIolioll, }lJifb lesse!led IIIIISCII/{/J'pOlJler, 
ill Ptll1s, 1101 ill flr/iOIl alld ""m Ipben Slippolted; Ipilb pmpeJIJil)' 10 belld Ibe Il'llllk jOI7l>ard, alld 10 pass 
jlVII/ a Jl'ttikilig 10 a rmllliftg pate; Ibe .reflses and illfdleds beiNg IIlIilijllred." Nowadays PD is 
known as a common neurodegenerative disorder charactcrh:ed by the clinical combi-
nation of tremor, bradykinesia, rigidity and postural disturbances. Additional features in 
PD are dementia, dysautonomia, dystonic cramps, postural abnormalities and asymme-
try of signs at onset. 
Neuropathologically, PO is characterized by a selective degeneration of the dopa~ 
lninergic neurons in the pars compacta of tlle substantia nigra, resulting in dopamine 
deficiency in striatal projection atcas of these neurons. The presence of neuronal inclu-
sions, kno\vn as Le\vy bodies, in the surviving dopaminergic neurons are generally con-
sidered as the pathologic hallmark of PO, albeit not totally specific.' 
In the elderly, PO is a major disabling disorder putting a high claim on health care 
budgets. The prevalence of PO varies from 0.6% for those aged 65-69 years to 4.3% 
for those aged 85 years and over.S The overall prevalence is 1.6% for individuals aged 
65 years 01' older.s Since the number of elderly individuals of the population is increas-
ing and individuals tend to live longer, we may expect an increase in the prevalence of 
PD, wllich could have major social and financial implications in out' current health care 
system. The etiology of PD is still largely unknown and treatment is symptomatic with 
only temporary results. However, currently it is generally accepted that PD is a geneti-
cally complex disease in wllich genetic factol'(s), cnviroll1nental factor(s) or a combina-
tion of both may determine the risk of PD. For many decades several investigators re-
ported clustering of PO in families.'·7 Studies on familial aggregation in PO with an 
autosomal dominant inheritance pattern have clearly indicated that genetic factors play 
a significant role in PD.' Fa111iliallinkage studies and candidate gene studies have been 
carried out to investigate tl1e role of genetic factors and the pattern of inheritance in 
PD but the results are controvcrsia1.6,7 The most convincing evidence that PD can be 
inherited as a single gene defect comes from families v.lith PD with an autosomal domi-
nant inheritance pattern '}-11 or with an autosomal recessive inheritance pattern. 12,1J At 
least nvo other loci have been found in relation with PD.14,15 These observations pro-
vide important evidence that PD is a genetically heterogeneous disorder. 
3 
Clmpter 1 
The objective of the work presented in this thesis was to study genetic susceptihility 
to PD. We did this in two different studies, the Rotterdam Study, which is a prospective 
population based cohort study on frequency, etiology, and prognosis of chronic dis-
eases, and a large European collaborative sib pair study on PD. We used different 
n1ethods. 
Firstly, as presented in chapter 2, we analyzed whether there was fanillial aggrega-
tion of PD. \'(le did this by assesing the risk of I'D in the Rotterdam Study as a function 
of a positive family history of PD or dementia. 
Secondly, we used genetic association studies, presented in chapter 3, to study can-
didate genes in PD. In chapter 3.1 and 3.2 we report the association between candidate 
genes, N-acetyltransferase-2 (NAT-2) Cytochrome 1'450 (CYP2D6) and I'D, within the 
Rotterdam Study. The risk of I'D with or without dementia as a function of the APOE 
genotype in the Rotterdam Study is presented in chapter 3.3. 
Finally, linkage studies and genetic association studies in affected sib pairs, were 
used to study genetic susceptibility to PO (chapter 4). In chapter 4.1 we present the 
study design and linkage results on chrolnosmes 2p and 4 in Parkinson's Disease in a 
large study of European affected sib pairs. Within the framework of this European 
study we also evaluated the importance of the reported mutations in the UCH-Ll gene 
(chapter 4.2) and the mutations in the Parkin gene (chapter 4.3). 
In chapter 5 the rmdings presented in this thesis are discussed in general together 
with issues relating to study design. Some mechanisms that may potentially underlie PD 
are considered and finally, we discuss clinical, social and scientific impact of our and 
other genetic studies in PD. 
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FAlvIILY HISTORY AND THE RISK OF 
PARKINSON'S DISEASE IN A PROSPECTIVE 
POPULATION-BASED STUDY 
Abstract 
Previous studies on familial aggregation of Parkinson's disease (PO) were mostly hospi-
tal-based case-control studies or pertained to younger individuals. We prospectively de-
termined the risk of PD according to family history of PO in a population-based cohort of 
6341 elderlv. After 5.3 year follow·up we identified 57 PO-patients. Persons with at 
least one first degree relative with PD had a 1.5-time higher risk, and persons with at 
least two first degree relatives had a five-time higher risk of PD. OUf study suggests that 
hereditary factors contribute to the occurrence of PO in the elderly. 
INTRODUCTION 
Several studies reported familial aggregation of Parkinson's disease (PD). However, 
most werc case-control Shltlies,\.(; mostly based on selected hospital populations in 
,,,hich the information had been collected retrospectively,l-4 or pertained to younger 
subjects.2~ Recently a large twin study on PD suggested that genetic factors arc only 
important \vhen the onset of disease is at or before age 50 years. 7 Because of these con-
siderations, it remains a question to ,,,hat extent a positive family history of PO in-
creases the risk of PD among elderly, unselected people from a general population. We 
prospectively assessed the risk of PD as a function of family history of PD or dementia 
in the Rotterdam Study. 
METHODS 
The study was part of the Rotterdam Study, an ongoing prospective population-based 
cohort study on frequency, etiology and prognosis of chronic diseases in the elderly.1:! 
9 
Chapter 2 
Bascline examinations were in 1990-1993; follo\v-up examinations took place in 1993-
1994 and 1997-1999. In addition, the cohort is continuously being monitored for major 
outcomes of interest through computer linkages with general practitioners' medical rec-
ords and pharmacies automated medical record systems. Until the end of Dccember 
1999, the proportion lost to follow up was less than I percent. 
Case ascertairunent and diagnosis ofPD 
The cohort examined at baseline for symptoms of parkinsonistll exists of 6969 partici-
pants and has been descrlbec.l extensively else\vhcreY Screening and diagnos tic proce-
dures \verc the same throughout the entire stuc.ly. Briefly, all participant.s were inter-
viewed about prcvious diagnosis of PD or anti-parkinsonian drug usc and screened for 
symptoms of parkinsonism by study physicians at the research center. All participants 
who either used anti-parkinsonian drugs, reported that they had PD or had at least one 
possible cardinal sign of parkinsonism (resting tremor, bradykinesia, rigidity, and pos-
tural disturbances) at the screening examination, got a sU1.1ctural diagnostic work-up by 
a neurologist.9 PD was diagnosed if at least two out of four cardinal signs and no other 
apparent cause of patkinsonism \vere present. For individuals who could not be re-cx-
amined in person for parkinsonism at follo\v-up, we obtained information through our 
surveillance system and checked their medical records. 
Study population 
The study population at risk for incident PD consisted of all persons who had a neu-
rologic screening examination at base-line, were free of parkinsonism and dementia at 
that time and ofwhol11 base-line data on family history were avaibble (n=6,341). 
Data collection on family history 
Data on family history for various diseases including PD and dementia among Hrst de-
gree rel'ltives were obtained as part of the base-line data collection in the Rotterdam 
Study. All participants were asked to indicate for each family mcmber whethe\' that 
family n1ember was affected by a specific disease. Formal pedigrees wcre constructed 
using data on year of birth and if applicable year of death of their parents, siblings, and 
children. 
10 
hlnlily history <'1nd the risk of Parkinson's disease 
Data analysis 
The follow up period ended either at the second screening examination, at age at onset 
of PD, parkinsonism 01' dementia, 01' at death. ,'lie used Cox proportional hazard mod-
els to estimate age and gender adjusted relative risks (lms) with the corresponding 95°;', 
confidence intervals (95%Cl) for a positive family history of PD. In addition, we cal-
culated the risk of PD according to a positive fanuly history for dementia. 
RESULTS 
The characteristics of the study population at risk for PD are listed in Table I. In our 
study population 64.8 % were ever smokers. After a total follow up time of 33,887 per-
sonyears with a mean follow-up duration of 5.3 year we had identified 57 cases with 
PD. The personyears of follow-up, incidence rates and adjusted RRs are listed in Table 
2. Persons with at least one relative \vith PD had a 1.5-time higher risk of PD whereas 
persons with at least t\vo relatives had a five-time higher risk of PD, albeit not signifi-
cant at the level of 5%. Adjusting for ever smoking status did not alter the point-esti-
mates. The risk of PD was sinlllat' for persons \vith 01' \vithout a positive family histot), 
of dementia. 
Table 1 
Baseline characteristics of the study population at risk of incident Parkinson's disease 
(PO). 
Number of persons at risk of PO 
Mean age in years (± SO *) 
Number of women (%) 
Number of persons with at least one relative with PO (%) 
Number of persons with at least two relatives with PO (%) 
Number of persons with at least one relative with dementia (%) 
" SD = standard deviation 
6,341 
68.5 
3,731 
313 
24 
1497 
(S.6) 
(5S.S%) 
(4.9%) 
(0.4%) 
(23.6%) 
I 1 
Table 2 
The incidence of Parkinson's disease (PO) in persons with a family history of PO, and in 
those without such history with corresponding adjusted relative risk (RR) with 95 % 
confidence interval (95%CI) of PD. 
Persons at Incident Person- Incidence RR (95%CI) Baseline family history risk of PD* PD cases* years rate* * 
Persons without a 6.028 53 32,181 1.7 1.0 (reO 
relative with PD 
Persons with at least 313 4 1,706 2.3 1.5 (0.5-4.1) 
one relative with PO 
Persons with at least 24 110 9.0 5.1 (0.7-37.1) two relatives with PO 
*Numbers of individuals; ** Incidence rate in cases per 1,000 person years; RRs 
adjusted for age and sex. 
DISCUSSION 
This is the first prospective populntion based study tbat investigated tbe risk of PD 
among elderly subjects according to history of PO in first degree relatives. \v/c found 
that individuals ,vith first degree relatives \vith PD in particular with at least two af-
fected first degree relatives had a higher risk to develop PD than pcnmns without such 
a family history. This suggests that genetic factors do playa role in sporadic late-onset 
PD. 
Our results did not reach statistical significance at the conventional S°!t) level, \vhich 
asks for a cautious interpretation of our findings. There are a number of reasons why 
we may have failed to find a statistically sif,rnificant effect. First, the po\ver in our study 
was limited. Although the present prospective population-based study is the largest in 
its kind, the number of incident cases was still relatively small. Furthel1nore, only a 
small proportion of all participants reported a positive family history of PD among first 
degree relatives. Second, \ve had to rely on self-reported family history of participants. 
Due to the size and the age distribution of this cohort, it was not feasible to verlfy the 
family history of each participant. This probably may have introduced some misclassifi-
cation of disease status of family members. Since all participants were tree of PD or 
dementia at baseline and were, like the interviewers, not a\vare of their future disease 
status, tills exposure misclassification was probably similar in those \vho developed PD 
and those \vho did not. Yet, it will have attenuated any existing effect. Third, since \ve 
only assessed family history at baseline and did not update tl1e disease status of relatives 
Filfllily histOf'Y <II](J 111co risk of Pnrkinson's disc-oHse 
of our cohort members during fullow-up, we will have misclassified the relatives \vho 
developed PO after our initial inquiry. Assuming that there is indeed familial aggrega-
tion of PD, tllls \vill have resulted in a more severe underestimation of the proportion 
with a positive family history uf PD among those \vho actually developed PD, anu 
hence in an underestin1ation of the relative risk. These considerations suggest that, if 
anything, we underestimated the relation between family history and the risk of demen-
tia in this elderly population. 
Our results seem at odds with a recently puhlished t\vin shldy that sugt:?;ested that 
heredity is not a major etiologic component in PD begi111llng after age 50 years. 7 H()\'l-
ever, that stuuy was cross-sectional and an average of almost 10 years c1apscu before 
the second twin was diagnosed with PD.7 n'Iore concordant pairs may be identified if 
the twins are followed over time. j\lureover, \'lith increasing age at onset in the first 
affected twin, the probability increases that the second twin will not survive long 
enough to develop PD. The study of heredity of PO in twins with late-onset PD is dif-
ficult, and negative results should be interpreted cautiously. Evidence that genetic fac-
tors may playa role in familial PD witl) an onset after age SO years came fron1 a recent 
report on Parkin mutations in Europe. 
1n conclusion, our findings suggest that genetic factors contrihute to the occurrence 
of sporadic I'D in the elderly. 
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N-ACETYLTRANSFERASE-2 
POLYMORPHISM IN PARKINSON'S DISEASE 
THE ROTTERDAtvI STUDY 
Abstract 
The N-acetyltransferase-2 (NA T-2) gene has been associated with Parkinson's disease 
(PD). The genotype associated with slow acetylation has been reported to be increased 
in PO patients. Three mutant alleles M1, M2, and M3 of the NAT-2 gene were investi-
gated in 80 patients with idiopathic PD and 161 age matched randomly selected controls 
from a prospective population-based cohort study. The allelic frequencies and genotype 
distributions in cases were very similar to those found in controls. In controls the fre-
quency of the wild type allele increased significantly with age suggesting that the mutant 
alleles are associated with an increased risk of mortality. These findings suggest that 
NA 1-2 polymorphism is not a major genetic determinant of idiopathic Parkinson's dis-
ease, but may be a determinant of mortality in the general population. 
INTRODUCTION 
Parkinson's disease (PD) is a common nellrodegenerative disorder among elderly peo-
ple. I.' The etiology of PD still remains largely unknown but most likely results f!'Om 
interaction between genetic and environmental factors . .1-5 Several functionally relevant 
PolYl11orphisms in xenobiotic metabolism have been studied in relation to patients with 
PD, but with no consistent reslllts/,,7 Explanations for these inconsistencies include 
different methodologies, different diagnostic criteria, poor selection of control groups 
and smail sample sizes. Recently, an association of slow acctylators for the NAT -2 gene 
with PD was reported.l:l The NAT-2 gene, which maps to clU'omosome 8p22'.),Hi, is as-
sociated with speed of acetylation of certain drugs and xenoblotics,9-11 Slow acetylators 
are homozygous for any of the mutant alleles and may be more susceptible to low-level 
environmental exposure to neurotoxins,H The finding of an increased frequency of 
subjects homozygous for the NAT-2 gene mutations is compatible with the view that 
1/ 
Chapter :3.1 
PO patients may be less capable to handle certain endogenous or exogenous toxins,12 
Ho\vever, the findings on the NAT-2 gene were not conf'irmed.1J The aim of this study 
was to investigate the possible association of the NAT-2 gene polymorphisll1in idio-
pathic PD. 
METHODS 
The study formed part of the Rotterdam Study, a prospective population-based cohort 
study on the frequency, etiology, and prognosis of chrome diseases. The cohort exists 
of 7,983 independently living or institutionalised inhabitants from a suburb of Rotter-
dam, the Netherlands, who are aged 55 years or older. The Rotterdam Study started in 
June 1990 and has been described extensively eisewhere,I4 Informed consent \vas ob-
tained from each participant and the study was approved by the Medical Ethics Com-
mittee of Erasmus University Rotterdam. Participants were screened at baseline (1990-
1993) and at follow-up (1993-1994) for symptoms of parkinsonism by shldy physicians. 
All screenpositives had a diagnostic investigation by a neurologist. PO \vas diagnosed in 
persons \vith at least two out of four cardinal signs (resting tremor, bradykinesia, rigid-
ity, and postural disturbances) and no other apparent cause of parkinsonistn.2 In the 
Rotterdam Shldy 97 prevalent and 35 incident PO patients were identified until 1994. 
Blood samples for DNA extraction and genotyping were available for 80 patients (68 
prevalent PO patients and 12 incident PO patients, mean age 77.3 (8.3), range 57.5-
99.2, 27 males and 53 females). POI' each case we randomly selected two age matched (± 
5 years) controls (mean age 76.8 (8.3), range 57.9-98.8, 63 males and 98 females) from 
the same study population who did not have PD and of \vhom bm;cline data regarding 
smoking history as well as blood samples were available. A polymerase chain reaction 
(PCR) was conducted using specific pCR primers for tl1e NAT-2 gene. IS The amplifi-
cation products \vcre digested using restriction enzymes, separated on an agarose gel 
and visualised with ultra violet light. We investigated the genotype of the NAT-2 gene 
using restriction enzymes KPIlI, Taqi and B(/JI/I-Il for mapping the three mutant alleles 
J'"l1, M2, M3 and the wild type allele of the NAT-2 gene.' Genotyping was performed 
on coded samples vvithout kn()\vledge of the clinical diagnosis of the suhjects. The ll1U-
tations fvll, 112) and fvI3 account for most of the sIo\v acetylators in Caucasian pa-
tients. IG Slow acetylators were defined as carrying any hvo of the mutant alleles 1-11, fvl2, 
and 1113. Allele frequencies were determined by counting alleles and calculating sample 
proportions. Allele frequencies and genotype frequencies were compared using Chi-
square statistics. 
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Table 1 
Age stratified and overall frequencies of acetylator genotypes in PD patients and controls from the Rotterdam Study. 
55-64 65-74 ;,75 overall 
genotype control case control case control case control case 
(n = 14) (n=7) (n=46) (n=22) (n=101) (n=51) (n=161) (n=80) 
WTIWT 0 0 0.11 0.14 0.04 0.06 0.06 0.07 
WT/Mx 0.29 0.86 0.30 0.27 0.49 0.37 0.42 0.39 
Mx/Mx 0.71 0.14" 0.59 0.59 0.47 0.57 0.53 0.54 
WT=wild type, Mx=any mutant allele M1, M2, or M3. *significant lower proportion of slow acetylator genotype as compared to 
cases (OR=0.067; 95%CI 0.06-0.75; Fisher Exact 2-sided P=0.024). 
RESULTS 
Genotype distributions \vere in Hardy-\X/einberg equilibrium. Prequendes of mutations 
in cases and controls and stratified on age are listed in the table. Overall, the ll1utation 
frequencies were vcry similarly distributed among cases and controls. 
The proportion of slow acetylators in the youngest age category, 55-64 years) was sig-
nificantly lower in patients compared to controls. An interesting observation \vas that 
the frequency of thc wild type allele in controls increased significantly with age 
(p,«nJ<O.OO I). 
DISCUSSION 
Our results do not confirm the association between the slo\v acctylator genotype for 
the NAT-2 gene and PD as \vas found previously,l! Sample size calculations \\'ith a 5% 
significance level sho\ved that 've had a power of 9()lX) in our study to detect differences 
in genotype frequencies at an odds ratio level of 2.5 for slo\v acetylators as was found in 
the study of Bandmann et al." This latter study was based on pathologically proven PD, 
\vhereas we used clinical diagnostic criteria to assess PD. One might consider that \ve 
misclassitled some patients in our study and that this ha:-; biased our estimates. It is 
highly unlikely however that the re:-;ulting bias, if any, would be big enough to explain 
the discrepant Endings. 11oreover, the overall frequencies of slow acetylator:-; in cases 
and controls found in our :->tudy are sinillar to that found in other studies. 13,17 
There are several other possible explanations for the discrepancy behveen our 
tlndings and those of Bandmann et al.H Firstly, they reported a significant association 
between the NAT-2 gene polymorphism and familial PD, but not with sporadic PD. 
Ho\vevei", the frequency of the slow acetylator genotype in sporadic PD in their initial 
analysis was significantly highcr as compared to controls (odds ratio=2.45; p=O.O(3) 
and after correction for multiple comparison the point estimate of the association re-
mained the samc but only became borderline significant (odds ratio=2.45; p=O.06). 
Secondly, the association between the NAT-2 gene and PD may not be due to a causal 
relationship but rather to the NAT-2 genc being in linkage disequilibrium with a neigh-
bouring gene that is involved in the etiology of PD. Thl:-; explanation is in line with the 
finding of a lower proportion of slow acetylators in the early-onset group in the present 
study \vhereas Bandmann et al.8 found a higher proportion of slow acetylators in PD 
patients as compared to controls. Thirdly, their controls came frol11 a heterogeneous 
population submitted to the UK Parkinson's Disease Brain Rank and the brain bank at 
N-acetylll'<lllsf(-:r,lSc-:-2 polYlnorplli8tll in PI) 
the institute of Psychiatry, London, UK and were not matched for ethnic background. 
This could explain the relatively low freguency of slow acetylators found in their con-
trol population as compared to our study and other studies i3,I7, and may have intro-
duced some bias. fourthly, we found that the frequency of the wild type allele in con-
trols increased significantly with age suggesting that the mutant allelcs arc associated 
with an increascd risk of mortality, possibly because of the incrcased risk of cancer for 
mutation carriers.7,tH This suggests that bias may he introduced if cascs and controls afe 
not matched for age which \vas the case in the series of Bandmann et al.H \vhere the 
mean age of the control population (77.1 years) was almost nine years higher than the 
mean agc from patients selcctcd from the familial cascs (68.4 years). A final explanation 
could be that sl<nv acetylators ate not only n10re susceptihle to neurotoxins \vhich are 
inactivated by an acetylation reaction!'!, but are sin1ultaneously less susceptible to poten-
tial neurotoxins which arc activated by acetylation. This dual activation-detoxification 
of the NAT-2 gene polymorphism makes the interpretation of any association debat-
able." 
The findings of this population-based study suggest that NAT-2 gene polymor-
phism is not a major genetic determinant of idiopathic PD, but may be a determinant 
of mortality in the geneml population. 
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CYP2D6 POLYMORPHISM 
IN PARKINSON'S DISEASE 
THE ROTTERDAM STUDY 
Abstract 
The CYP2D6 polymorphism has been studied extensively in association with Parkinson's 
Disease (PD), with no consistent results. Several explanations, like differences in study 
design or bias in the selection of the control population have been offered for these in-
consistent results. We designed a case-control study nested within a prospective popula-
tion based cohort study in which cases and controls were sampled from the same source 
population. To assess the significance of the CYP2D6 gene in PO, we investigated two 
mutant alleles, CYP206*3 and CYP206*4, associated with poor metabolism and the 
wild type allele in 80 patients with PO and 156 matched controls, frequency matched on 
age and gender. No differences between cases and controls were found for the poor me-
tabolizer genotype. However, we found that in contrast to earlier reports, the CYP2D6*4 
mutant allele frequency was lower in cases as compared to controls, albeit not statisti-
cally significant. Our result supports the hypothesis that the CYP2D6 gene is not a major 
gene responsible for PD. 
INTRODUCTION 
Parkinson's disease (PD) is a common disabling disorder among elderly characterized 
by a progressive neuronal degeneration in the nigrostriatal system.! Clinically, PD is 
characterized by the presence of resting tremor, bradykinesia, rigidity and postural dis-
turbances. Several environmental and genetic factors have been suggested to playa role 
in the etiology of PD. Of all candidate genes studied thusfar, the CYP2D6 gene has 
been studied most extensively. It has been suggested that poor metabolizers of debriso-
quine have an increased risk of PD.2,3 After the initial report of Smith and colleagues in 
19923, several studies regarding the association between PO and the CYP2D6 gene 
have been published ,vith no consistent result.4 A meta-analysis of the association be-
t\veen the- CYP2D6 gene and- PD sho,ved a slightly increased, borderline significant, 
:>3 
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risk of PD in poor metabolizers.4 Exclusion of the only statistically significant study3 
increased the P-valuc of the tneta-analysis however to 0,5, Despite all effort put .in 
studying the association of the C\'P2D6 gene with PO, the hypothesis that poor me-
tabolizers are at greater risk of PD could neither be supported nor refuted.s Different 
diagnostic criteria across studies, different shldy designs, small sample sizes and in par-
ticular poor control selection may have played a role in these inconsistent rcsults, 
To avoid several epidemiological pitfalls in studying the C'I'P2D6 gene in PO, we 
designed a case-control study nested \vidun a population based cohort shldy in which 
cases and controls were sampled from the same source population, to investigate the 
significance of the C\'P2D6 gene in PD. 
METHODS 
This study was nested within the Rotterdam Study, a prospective population-based co-
hort shldy on the frequency, etiology, and prognosis of neurologic, cardiovascular, lo-
comotor and ophthalmologic diseases. The Rotterdam Study started in June 1990 and 
has been described extensively elscwhere,c, The cohort examined for sympto111s of PD 
exists of 6,969 independendy living or institutionalized inhabitants from a suburb of 
Rotterdam, the Netherlands, who are aged 55 years or older, Informed consent was 
obtained from each participant and the study was approved by thc lvIedical Ethics 
Committee of Erasmus 11edical Center Rotterdam, Participants \vere screened at base-
line (1990-1993) and at follow-up (1993-1994) for symptoms of parkinsonism by study 
physicians, All screenpositives got a diagnostic \vork-up by a neurologist. PO was diag-
nosed in persons \vith at least two out of four cardinal signs (resting tremor, bradykine-
sia, rigidity, and poshlral disturbances) and no other apparent cause of parlcinsonism,7 
In thc Rotterdam Study 97 prevalent and 35 incident PD patients were identified until 
1994. Blood samples for DNA extraction and genotyping were available for 80 patients 
(68 prevalent I'D patients and 12 incident PD patients, mean age 77.3 (8.3), range 57.6-
99.2,29 males and 51 females) and 156 randomly selected controls, frequency matched 
on age (in 5 years age categories, mean age 76.6 (8.3), range 57.9-98.8) and gender from 
the same study population who did not have PD nor parkinsonism and of whom base-
line data regarding smoking history as well as blood samples wefe available, 
\'Ile investigated the C)'P2D6 limctional wild type allele (CYP2D6wt) and two de-
fective mutant alleles classified as C)'P2D6*3 and CYP2D6*4' in association with PD. 
These two mutant alleles compromise approximately 90%1 of the poor metabolizers 
among Caucasians in EumpeY Gcnot),ping was performed simUarly to a preyiously .rc-
CYP?DG polymorphism in PO 
ported study' on coded samples without knowledge of the clinical diagnosis of the par-
ticipants. Pm the evaluation of the genotype distribution, the CYP2D6 alleles were clas-
sified according to functional activit), as wild type (wt) and mutant (mut). Individual 
genotypes \vere characterized as either homozygous for the wild type (\vt/wt), hetero-
zygous (nluthvt) or homozygous mutant (mut/mut). Allele frequencies were deter-
mined by counting alleles and calculating sample proportions. Allele frequencies and 
genotype distributions \vere compared using Chi-square statistics. Logistic regression 
analysis methods were used to calculate odds ratios (ORs) \vith 95%) confidence intc1'-
vals (95%,Cl) for the association behveen the heterozygous and homozygous mutant 
genotypes and PD as compared to controls. The homozygous wt genotype was used as 
the reference category. In the analysis \VC adjusted for age, sex and ever smoking. 
RESULTS 
Genotype distributions in controls were in Hardy-W1einberg equilibrium. The distdbu-
cion of the CYP2D6 genotypes and alleles in cases and controls arc listed in Table 1. 
No significant differences \vere found for the allele frequencies behveen cases and 
controls. However we observed that the frequency of the C'{P2D6*4 allele was unex-
pectedly lower (OR = 0.72; 95')'oCI 0.45-1.19) in cases as compared to controls, albeit 
Table 1 
Distribution of CYP206 genotypes and alleles in Parkinson's disease (PO) and controls. 
Controls PO-cases 
genotypes n frequency n frequency 
wt/wt 90 0.58 57 0.71 
wt/*3 48 0.31 15 0.19 
*3/*3 11 0.07 5 0.06 
wt/*4 7 0.04 0 0 
*3/*4 0 0 3 0.04 
Total 156 1 80 1 
alleles 
wt 235 0.753 129 0.806 
CYP2D6*3 7 0.022 3 0.019 
CYP2D6*4 70 0.225 28 0.175 
Total 312 1.00 160 1.00 
wt = wild type allele; *3= CYP206*3 (basepair deletion); "4 = CYP206"4 (G-A transition) 
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Table 2 
Genotype distributions of the CYP2D6 gene in PO cases and controls and the 
association between CYP206 genotypes and PO as compared to controls. 
Controls Cases OR (95%CI) adjusted for: 
frequency frequency 
Genotype (n~ 156) (n~80) age & sex 
wt!wt 0.58 0.71 ref. 
wt!mut 0.35 0.19 0.43 (0.22-0.83) 
mut/mut 0.07 0.10 1.18 (0.44-3.15) 
Z'~6.99; P = 0.03; df=2 
n = number of study participants; ref. = reference category 
wt = wild type; mut = mutant alleles CYP2D6 ~ 3 = base pair deletion; 
CYP2D6 * 4 = G-A transition 
age, sex & smoking 
ref. 
0.37 (0.18-0.76) 
1.28 (0.47-3.43) 
not statistically significant. No significant differences bet\veen cases and controls \vere 
found for the CYP2D6*3 allele (Fisher's exact test two tailed, p= 1.0). The distribution 
of the pooled heterozygous or homozygous mutant genotypes and corresponding ORs 
with 95°A1CI for the association hef:\veen the heterozygous or homozygous mutant 
genotypes in PD as compared to controls are presented in Table 2. Among PD patients 
there were 57.6 percent ever sl110kers and among controls 50.8 percent. 
Overall, we observed significant differences in the genotype distribution bef:\veen 
cases and controls (X2=6.99; p=O.03; df=2). This occurred merely due to a lower fre-
quency of the heterozygous genotn)e in cases as compared to controls. The frequency 
of the heterozygous genotype was significantly lower (p=O.Ol) among patients Witll PD 
as compared to controls whereas the homozygous mutant genotype \vas slightly in-
creased in the cases, however not significantly. 
DISCUSSION 
Within this population based cohort study we found a significantly lower frequency of 
the heterozygous genotype among patients with PD as cOll1pared to controls from the 
same source population. WTe did not observe a significant difference in the frequency of 
the homozygous mutant genotype bef:\veen cases and controls. The frequency of the 
CYP2D6*4 allele was lo\ver among patients with PO as compared to the control 
population. These results .. were contrary to the initial report of Smith and colleagues' 
and also in contrast to a recently published meta-analysis on the CYP2D6 genotype and 
CYI'2DG polymorphism in PI) 
PD.4 The CYP2D6*4 association with PD in our study was not consistent with a ge-
netic causal mechanism because the decrease in frequency \vas found for the heterozy-
gates but not for the h01110zygotes. 
The strength of the present study is the usc of a population based cohort with sys-
tematic data collection and classification of PD. All participants were examined in per-
son and diagnosis of PD was made by neurologists. Controls \vere, in contrast to 1110st 
other studies of the CYP2D6 gene in PD3,4, randomly selected from the satne source 
population where the cases came fron1 and frelJ.uency matched on age and gender. This 
minimizes the probability of bias due to poor control selection. A limitation is the 
number of cases \vhleh is relatively small and hence yields little power. 
How should \ve interpret our findings and the discrepancies across studies? Firstly, 
since so many studies between I'D and the C,'1'2D6 gene have been published without 
consistent results and our results also do not provide evidence for an association be-
tween the C,'1'2D6 gene and PO, it is most likely that this gene does not affect the sus-
ceptibility to PD. A second explanation for the inconsistent results could be that PO is 
a genetically heterogeneous disorder. In a genetic complex trait like PO it could be pos-
sible that more than one genetic factor may determine the risk of PD. This complicates 
the reproducibility of a candidate gene association study, like the CYP2D6 gene in PO, 
in different populations with different genetic backgtound and ethnic origin. Thirdly, 
difficulties reproducing candidate gene studies may result from interaction \vith envi-
ronn1ental factors. Smoking, for example, has been inversely associated with PD and 
pOOl' metabolizers may smoke less. JO This, in part, could explain the conflicting findings 
due to confounding by smoking, since most studies4 did not adjust for s1110king in their 
analysis. However, adjusting for smoking in our analysis did not alter our results. Other 
factors that might interact with the C)'1'2D6 gene in causing PO include exogenous 
neufotoxins like j\{PTpll or pesticides l2 or endogenous isoquinolines. u Hitherto, there 
is no clear evidence that these interactions may cause PD. Finally, the CYP2D6 gene 
may be in linkage disequilibrium with another susceptibility locus in the same region. 
Up to present there is one report that tested the hypothesis of linkage disequilibrium 
and provided evidence that the C,'1'2D6 gene may be in linkage disequilibrium with 
another, yet unidentified locus responsible for susceptibility to PD,14 Our results do not 
support the hypothesis of linkage disequilibrium since we would expect a lower pro-
portion of both the heterozygous genotype and homozygous mutant genotype in cases 
as compared to controls which \vas not the case. 
Although we cannot fully exclude that the C,'1'2D6 gene may have an effect in a 
subgroup of PD patients through interaction with exogenous or endogenous toxins, we 
can conclude that the C,'1'2D6 gene is not a major gene in PO in the elderly. 
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APOE AND THE RISK OF 
PARKINSON'S DISEASE WITH OR WITHOUT 
DEMENTIA IN A POPULATION-BASED STUDY 
Abstract 
The objective of this study was to investigate the association between apolipoprotein-E 
genotype (APOE) and Parkinson's disease (PO) with or without dementia. The study 
formed part of the Rotterdam Study, a prospective population based cohort study on the 
frequency, etiology, and prognosis of chronic diseases. The cohort examined for PD 
exists of 6969 independently living or institutionalized inhabitants from a suburb of 
Rotterdam, the Netherlands, who are aged 55 years or older. All participants were 
screened at baseline (I 990-1993) and at follow-up (1993-1994) for symptoms of 
parkinsonism by study physicians and screenpositives got a diagnostic work-up by a neu-
rologist. APOE gena typing was available for 107 PO patients (26 with and 81 without 
dementia) and 4805 non-parkinsonian controls. The presence of at least one £2-allele 
significantly increased the risk of PO (OR~ 1.7; 95%CI:I.0-2.8). When we looked sepa-
rate/y for demented and non-demented PO patients as compared to non-parkinsonian 
controls, APOE appeared not associated with PO without dementia, but both the (;2-allele 
and the &4-allele increased the risk of PO with dementia (OR~ 5. 6; 95%CI:2.0-15. 2 and 
OR=3.6; 95%CI: 1.3-9.9 respectivelv). The risk of dementia for (;4-allele carriers was not 
significantlv different for persons with or without PD. However, the &2-allele stronglv 
increased the risk of dementia in patients with PD (interaction p < 0.007). 
We conclude that in the elderlv the APOE (;2-allele increases the risk of PD and in 
particular the risk of PD with dementia. 
INTRODUCTION 
It has been suggested that Parkinson's disease (PO) and Alzheimer's disease (AD) share 
clinical and neuropathologic features. t .3 It is known that PO patients frequently develop 
dementia, and AD patients frequently develop parkinsonism, Both are age-related dis-
orders characterized by intraneuronal inclusion bodies:t 
The apolipoprotein 84-allele has been associated witl, both ADS and Lewy Body 
disease (LBO)."" Reports on APOE genotype and PO are not consistent. Some studies 
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reported an association between the apolipoprotein ~A-allele and PD or PD with de-
mentia whereas others did not. ti ,') In the n1ajor1ty of these studies little attention has 
been paid to the E2-allele and PD. Ho\vever, 1n n10st of these studies, but not a11,10 the 
€2-allele frequency \vas higher in PD patients,ti, 11·13 or in PD patients with dementia,14,15 
albeit not statistically significant. Recently a significant association of the s2-aUele with 
sporadic PD has been reported, ho\vever no subdivision \vas made bel:\veen demented 
and non-demented I'D patients." We studied differences in the AI'OE genotype distri-
bution among PD patients \vith and \vithout dementia as compared to non-parkinso-
nian controls from the Rotterdam Study. 
METHODS 
Study population 
The study formed part of the Rotterdam Study, a prospective population based cohort 
shldy on frequency, etiology and prognosis of neurologic, cardiovascular, locomotor 
and ophthalmologic diseases as has been described previouslyY Briefly, all inhabitants 
of a suburb of Rotterdam, aged 55 years and over, including those living in the homes 
for the elderly, were invited to participate. A total of 7983 (response rate 78 percent) 
individuals agreed to participate and of these, 6969 (68%) individuals participated in the 
screening of parkinsonism at baseline (1990-1993) as described extensively elsewhere. IS 
Infof1ned consent was obtained from each participant and the shldy was approved by 
the j\Iedical Ethics Committee of the Erasmus Medical Center Rotterdam, The Neth-
erlands. 
Case ascertainment and diagnosis of PD 
All 6969 participants were interviewed about previous diagnosis of PD or anti-parkin-
sonian drug usc and screened for symptoms of parkinsonisln by study physicians at the 
research center. All individuals who either used anti-parkinsonian drugs, reported that 
they had PD or had at least one possible cardinal sign of parkinsonism (resting trelnOf, 
bradykinesia, rigidity, and postural disturbances) at the screening examination, got a 
structural diagnostic \vork-up by a neurologist. PD was diagnosed in persons with at 
least I:\vo out of four cardinal signs and no other apparent cause of parklnsonism,ll~ At 
baseline of dle 129 individuals with parkinsonism 98 had PD. The causes of parkin-
sonism were: parkinsonism associated with dementia (9); drug induced parkinsonism 
:m 
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(3); parkinsonism related to vascular disease (I); multi system atrophy (2); progressive 
supranuclear palsy (I) and other parkinsonism (15) which included parkinsonism and 
dementia \vith no clear time relationship between dementia and parkinsonism or more 
than one possible cause as \vell as those subjects in whom all causes of PD could be 
excluded but who had not shown any progression over more than 15 years in the 
course of disease and \vho did not respond to antiparkinsonian drugs.!t; At follow-up 
(1993-1994), 6840 participants, screened for symptoms of parkinsonism at baseline, 
were at risk to develop parkinsonism. Participants who were demented at baseline, were 
considered at risk for parkinsonism but not for PD. Follo\v-up information was avail-
able on 6778 (99'Yu) individuals either through completely re-examination at the re-
search center or through our surveillance system that continuously monitors the total 
cohort for interval cases of parkinsonism. Through this surveillance system that con-
sists of computer linkages with general practitioners and pharmacies automated medical 
record systems, we were notified of incident cases of parkinsonism, including PD, and 
had access to their medical records. A total of 5,3tO participants \vere completely re-
examined similarly to the two-phase design used at baseline. Of those \vho could not be 
re-examined, 449 had died, 558 refused screening examinations and in 461 the screen-
ing examination was incomplete. In the follo\v-up period, 62 individuals ,vith parkin-
sonism were identiHed of \vhom 35 had PD, three of whom with dementia. The other 
causes of parkinsonism were very similar to those at baseline: parkinsonism with de-
mentia (8 of \vhom 6 were already demented at baseline); drug induced parkinsonisn1 
(1); multi system atrophy (2) progressive supra nuclear pals), (I) and other parkinsonism 
(15) which included parkinsonism and dementia with no clear time relationship be-
t\veen dementia and parkinsonism (7), subjects \vith more than one possible cause, and 
subjects in whon1 all other causes of parkinsonism could be excluded but who did not 
respond to anti-parkinsonian drugs (8). Neuroin1aging \vas only performed in subjects 
in which the cause of parkinsonism \vas not obvious from physical examination alone 
(n=20,35%). 
In total 133 individuals were identified with I'D of whom 107 patients had the 
APOE genotype. Of these 107 patients 26 were diagnosed as I'D with dementia and 81 
a~ PD \vithout dementia. From the 26 PD patients \vith dementia, in nine individuals 
the diagnosis was obtained fr0111 general practitioner~ in \vhich eight were conHrmed by 
a neurologist not affiliated to our institute. From the 81 PD patients without dementia, 
in 12 individuals the diagnosis \vas obtained from the general practitioner in which to 
were confirmed by a neurologist. All other PD patients \vere seen in person and the 
diagnosis \vas made by the neurologists affiliated to our department. In total six of dle 
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61 I'D patients with APOE genotyping who were not demented at baseline developed 
dementia at follo\v up. 
Diagnosis of dementia 
A three-phase design was used, both at ba:o;eline and at follow-up, to diagnose dementia 
according to the American Psychiatric Association's criteria (DSn<f-IlI-R)19 and has 
been uescribed clse\vhere.21J,21 Briefly, all pafticipants wefe screened with a cognitive 
test; those who screened positive underwent further neuropsychological testing and 
those suspected for dementia \vere examineu in detail anu, if possible, had a Idagnetic 
Re:o;onance l111aging brain scan made. Of suhjects who could not be examined in per-
son, diagnosis was obtained from the general practitioner and medical records through 
our sULveillance system. For the diagnosis PD with dementia, the onset of PD had to 
cleady precede the onset of dementia. 
Apolipoprotein E genotyping 
1\POE gena typing was performed on coded DNA-samples of the total cohort as de-
scdbcu pteviously,22 without knowledge of the clinical diagnosis. In summary, polymer-
ase chain reaction was conducted and the amplification products \vere digested with 
Hbal, separated on an agaro:o;e gel, stained \vith ethidium hromide and visualized \vith 
UV-light. The results were analyzed by three independent experts. The APOE geno-
typing \vas repeated in case of discrepancies. 
Data analysis 
We used multivariate logistic regression anal),sis to calculate the odds ratios (OR) with 
95cyo confidence inteL-vals (95tYoCI) to assess whether the presence of at least one £4-
allele (APOE*4) or at least one 82-allcle (APOE*2) was associated with I'D, with or 
\vithout dementia as compared to non parkinsonian controls from the Rotterdam 
Study. Tn this logistic model I'D was the dependent variable whereas APOE genotype 
(with dummy indicating 1\POE*4, APOE*2 and APO£3£3) was the independent vari-
able. The most frequent genotype APOE3E3 was used as the reference. Adclitionally 
we used multivariate logistic regression analysis to examine the risk of dementia in PD 
patients as compared to non-parkinsonian controls, stratified by APOR genotype. In 
this model dementia was the dependent variable whereas I'D, APOE genotype and the 
multiplicative intemction between PD and APOE were used as independent variables. 
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To test whether our results \verc not merely due to misclassificaclon of AD as PD \vith 
dementia, \ve conducted similar analyses for patients \vid1 dementia with parkinsonism 
from the same study population. The diagnosis dementia with parkinsonism was made 
for patients \vith at least two cardinal signs, with no other apparent cause of parkinson-
ism except dementia taking into account that the onset of dementia had to clearly pre-
cede the onset of parkinsonism or both were diagnosed at the same time. ivIoreovet', to 
rule out the possibility of survivorship bias as an alternative explanation for our results, 
we used COX proportional hazard models to firstly determine prospectively if the 
presence of an s2-allele or an s4-allele increased the risk of PD and secondly to deter-
mine the risk of the development of dementia during longitudinal follow-up in PD pa-
tients who were not demented at baseline. In the first analysis PD was the dependent 
variable and the APOE genotype the independent variahle, \vhercas in the second 
analysis dementia was the dependent variable and APOE genotype tl,e independent 
variable. In all analyses we adjusted for age at examination at baseline and gender and 
we excluded subjects Witll the APOE2E4 genotype since this genotype may obscure 
differences between APOE*2 and J\POE*4. 
RESULTS 
The characteristics of tl,e study population and the APOE genotype distributions are 
summarized in Table 1. After exclusion of participants with the APOE2E4 genotype 
(three patients with PD and 132 non-parkinsonian participants), APOE genotype for 
the analyses was available for 104 I'D patients ( 22 prevalent and three incident PO 
with dementia and 55 prevalent and 24 incident PO without dementia) and 4673 non-
parkinsonian controls. All genotype distributions were in Hardy-\\Ieinberg equilibrium. 
The crude and adjusted ORs with 95%Cl for the associations between the APOE 
genotype with PD, \vith and without dementia are listed in Table 2. Persons with at 
least one €2-allele had significantly mote often PO (OR= 1.7; 95%,CT: 1.0-2.8). \'(Ie 
found no association between the €4-allele and PD (OR= 1.0; 9S%,CI: 0.6-1.6). For 
non-demented PD patients as compared to non-parkinsonian subjects, no association 
was found for either the €2-allele (OR= 1.2; 95%CT: 0.7-2.2) or the €4-allele (OR=0.7; 
9S%Cl: 0.4-1.2). However, both the 82-allele (OR=5.6; 9S°/r,CI: 2.2-15.2) and the €4-
allele (OR 3.6; 9S%Cl: 1.3-9.9) strongly increased the risk of PD with dementia. To 
assess whether these findings could be explained by n-llsclassiflcation of AD as PD with 
dementia, we perfof1ned sinillar analyses for 27 patients with dementia with parkinson-
Table 1 
The characteristics and the distribution of the APOE genotype and alleles of the study population. 
All PO PO without PO with Dementia with Controls dementia dementia parkinsonism 
(n = 1 07) (n=81) (n=26) (n=27) (n =4805) 
age (SO) 77.4 (8.0) 75.8 (7.8) 82.1 (6.7) 84.0 (6.0) 69.0 (8.6) 
proportion men (%) 35.5 37.0 30.8 29.6 44.8 
APOE genotype frequency % (n) 
apoe <31<3 54.2 (58)' 62.9 (51) 26.9 (7) 37.0 (10) 57.9 (2783) 
apoe <2/<2 0.9 (1) 0(0) 3.8 (1) 3.7 (1) 0.8 (38) 
apoe <2/03 20.6 (22) 17.3 (14) 30.7 (8) 11.1 (3) 13.0 (625) 
apoe <21<4 2.8 (3) 2.5 (2) 3.8 (1) 0(0) 2.7 (132) 
apoe <3/£4 20.6 (22) 16.1 (13) 34.6 (9) 44.5 (12) 23.0 (1106) 
apoe £41<4 0.9 (1) 1.2 (1) 0(0) 3.7 (1) 2.5 (121) 
APOE allele frequency 
apoe *2 12.6 (27)' 9.9 (16) 21.2 (11) 9.3 (5) 8.7 (833) 
apoe *3 74.8 (160) 79.6 (129) 59.6 (31) 64.8 (35) 75.9 (7297) 
apoe 0);'4 12.6 (27) 10.5 (17) 19.2 (10) 25.9 (14) 15.4 (1480) 
!numbers of subjects are given in parentheses. 
t numbers of alleles are given in parentheses. 
Table 2 
The association between the APOE genotype and Parkinson's disease (PD) with and without dementia and 
dementia with parkinsonism. 
All PO PO without PO with Dementia with 
APOE genotype dementia dementia parkinsonism 
(n= 1041 (n=791 (n=251 (n=271 
APOE3E3 1.0 (refl 1.0 (refl 1.0 (refl 1.0 (refl 
APOE*2 
crude 1.67 (1.01-2.721 1.15 (0.63-2.091 5.40 (2.00-14.541 1.68 (0.53-5.371 
adjusted * 1.69 (1.03-2.801 1.18 (0.65-2.171 5.55 (2.02-15.221 1.69 (0.52-5.551 
APOE*4 
crude 0.90 (0.55-1.461 0.62 (0.34-1.131 2.91 (1.08-7.851 2.95 (1.28-6.741 
adjusted * 0.98 (0.60-1.61 I 0.67 (0.36-1.221 3.60 (1.31-9.871 4.10 (1.73-9.741 
"Values are odds ratios adjusted for age and gender with 95% confidence intervals in parentheses. 
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ism. We found a strong association for the 64-allcle (OR=4.1; 95%,CI: 1.7-9.7) as ex-
pected, but no association for the 62-allele (OR= 1. 7; 0.5-5.6) with dementia with par-
kinsonis1l1 (Table 2). \\/hen we restricted ourselves to incident cases of PD) we found 
results that were sil11i1ar to those found fOt' the entire group of I'D (adjusted OR for at 
least one 62-allele: OR=2.0; 95%,CI: 0.8-5.2, for at least one 84-allelc: OR=1.5; 95";;,Cl: 
0.6-3.6). When we looked prospectively at the risk of dementia in PD patients not de-
mented at baseline) we found that the presence of at least one 82-allelc strongly in-
creased the risk of dementia (OR=13.5; 95%CI: 1.3-136.2); for presence of at least one 
64-allele we found no such relation (OR= 1.5; 95%Cl:0.6-3.7). 
The ORs \vith 95(YoCI for the association between PO and dementia stratified on 
the APOE genotype are listed in Table 3. Overall, patients with PD had an almost three 
times higher risk of dementia as compated to non-parkinsonian participants. This ap-
peared entirely due to the increased risk of dementia among PO patients \vith either an 
AI'OE*4 or APOE*2 genotype. The strength of the association between I'D and de-
mentia in the APOE*2 stratum as compared to the APOE*4 stratum or the APOE3E3 
stratum) suggested multiplicative interaction between PO and the APOE*2 genotype. 
Adding a multiplicative interaction term of I'D and the APOE genotype to the multi-
variate model) revealed a strong interaction behveen the APOE*2 genotype and PD 
(p<O.OO7). 
Finally) we verified the well-established association of the 84-allele with dementia in 
the control population (n=4763). As expected, the presence of at least one 84-allele 
significantly increased the risk of dementia (OR=2.2; 95'Y"Cl: 1.7-2.9), whereas the 82-
allele was not associated witl1 dementia (OR 0.8; 95'1oCl: 0.5-1.2). 
Table 3 
The risk of dementia in Parkinson's disease patients stratified by the APOE genotype. 
APOE genotype Overall APOE3E3 APOE*4 APOE*2 (n=4777) (n=2841) (n = 1250) (n=686) 
Non-parkinsonian 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
controls 
PO cases 
crude 6.2 (4.1-9.3) 2.2 (1.0-4.9) 7.3 (3.1-17.2) 14.6 (5.8-36.5) 
adjusted '* 2.8 (1.8-4.5) 0.9 (0.3-2.1) 2.5 (0.9-6.8) 7.7 (2.2-27.3) 
=104) (n=58) (n=23) (11=23) 
*Values are odds ratios adjusted for age and gender with 95% confidence intervals in parentheses. 
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DISCUSSION 
In this study among the elderly we found that carriers of the apolipoprotein E2-allcle 
had a significantly increased risk of PO, in particular of PO with dementia, and that 
presence of at least one E2-allele nmltiplied the risk to develop dementia in PD patients. 
The apolipoprotein E4-allele was not associated with PD overall, but, as expected, the 
E4 allele increased the risk of dementia in PD patients in a very similar wny as it in-
creases the risk of dementia in the general population. No associations were found for 
the APOE genotype with I'D without dementia. 
One should consider \vhether our Hndings could result from bias, in particular mis-
classification, selection or sU1'vivnl bias. \\fe consider misclassification of AD or LBD 
patients as PO patients with dementia unlikely, as we carefully restricted the diagnosis 
PO to those in \vhom the onset of parkinsonian signs had clearly preceded the cogni-
tive changes in ahsence of other clinical features. j\.{oreover, if misclassification \vould 
have occurred, it might, in part, account for the associations \ve found for the 84-allele 
but not for the H2-allele. Selection bias is a potential threat in association studies. Tn 
contrast to other studies,i:\,'} our control population \VaS hoth derived fr0111 the same 
source population as the PO patients and hased on a general, not necessarily healthy, 
elderl), population, including institutionalized persons. This minimized the possibility of 
selection bias in our study. Finally, since the E2-allele has been reported to be a genetic 
factor for longevity,23 one should consider that our findings might he a result of selec-
tive sUlyival. In order to rule out bias due to selective stu-vivorship we looked at the risk 
of dementia prospectively in non-demented PD patients and found that presence of the 
E2-allcle did increase the risk of the development of dementia in non-demented PD 
patients. Although the confidence interval of the point estimate was wide, mainly due 
to the small sample si%e, these results confirm the overall findings. j\foreover, we stud-
ied survival of carriers of the E2-allele in the Rotterdam Study, but found no association 
between APOE*2 and sUl'vival (unpublished data). Hitherto, only one stud), reported 
an association between the E2-allele and PO, however \vithout distinguishing bet\veen 
PD patients \vith or \vithout dementia. Ie, Nevertheless, when \ve reviewed the studies 
that investigated APOR genotype in relation to PD, we found that in most of then1 the 
frequency of the E2-allcle in PD patients,H, 1l·1J or in PD patients with dementia 14,IS was 
actually increased, albeit not statistically signiHcant. These other observations corrobo-
rate our view that the association that we found for the E2-allcle with PD with dementia 
is true. However, the population screened in this St1fyey \vas aged 55 ye.ars a.nd ove.r and 
therefore our findings may not generalize to younger patients with PD. 
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It is as yet unclear what might be the underlying pathulogic mechanism. \\lhereas 
the £4-allcle occurs at an increased frequency in AD,2' and p-amyloid plaques and 
neuro-fibrillary tangles (NFT's) arc increased in the brains of individuals with the £4-
allele as compared to those v,rho lack the 8-4 allelc,25,2(, the 82-aUele does not increase 
tbe risk of AD. If anything, it has been suggested to playa protective role in AD and 
senile plaque formation.24,27 Interestingly however, recently a high frequency of the 82-
aUele in a subset ofNFT-predominant senile dementia has been reported.2H The authors 
hypothesized that this type of dementia was distinct from AD." 1'vIoreover, the e2-allele 
has been associated with Argyrophilic Grain Disease,29 and an assuciation of the 82-
allele with cerebral amyloid angiopathy has becn reported.]() 
The strong association of APOE*2 \Vitll PD with dementia and not with PD with-
out dementia or dementia with parkinsonism and the observatiun that the E2-aUele 
strongly increases the risk of dementia in non-demented PD patients suggests that PD 
with and vlitll0Ut dementia have, at least partly, a different pathogenesis. Further re-
search to elucidate a possible specific role of the 82-allele in neurodegeneration is re-
quired. 
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The European sib pair study 

STUDY DESIGN FOR A GENOME-
WIDE SCREEN FOR SUSCEPTIBILITY GENES 
IN PARKINSON'S DISEASE IN EUROPE 
AND LINKAGE RESULTS ON CHROMOSOME 
2PAND4 
Abstract 
In the last few years evidence increased that genetic factors influence the occurrence of 
Parkinson's disease (PD). We established a European Consortium on Genetic Susceptibil-
ity in PO (GSPD) with the objective to study other, not yet identified, susceptibility genes 
in affected sib pairs with PD. We present here the overall design of the study and results 
from genetic analyses on three chromosomal regions that are of interest in PD (2p, 4p, 
4q). 
The GSPD-study started in 1995 with the recruitment of families with at least two 
affected siblings with PD and was conducted in five European countries. The diagnosis 
PO was made if proven pathologically or if three out of the four cardinal signs (bradyki-
nesia, rigidity, resting tremor, asymmetry of signs at onset), at least a 30 % improve-
ment with levodopa and no exclusion criteria were present. All the affected family mem-
bers were personally examined, videotaped and blood samples were taken using a stan-
dardised protocol. In addition blood was collected from parents and unaffected siblings. 
Up to the end of 1999 a total of 194 affected sib pairs from 176 families was identified. 
For the current analyses regarding chromosome 2p, 4q and 4p we genotyped 125 highly 
informative families with PD using 12 DNA-markers. 
We observed a nominal p-value lower than 0.05 for the pairwise lod score on 
D2S1394, suggesting the presence of a susceptibility region. Country-specific lod scores 
suggested possible linkage to the PARK3 locus for German sib pairs. 
We have successfully established a European Consortium and recruited a large num-
ber of affected sib pairs with PD for a genome wide search for susceptibility genes in 
PD. Our initial analyses did not reveal significant susceptibility regions on Chr 2p, 4p and 
4q. 
INTRODUCTION 
Parkinson's disease (PD) is a common neurodegenerative disorder among the elderly.l,2 
In Europe the overall age-standardised pi"evalence for PO in subjects' 55 years or older 
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is 1.6 per 100, with an increasing frequency up to 4.3°;(1 in those aged 85 years and 
over.2 Despite intensive efforts, the cause of PD remains still largely unlmo\vn and 
treatment is symptomatic ,,,ith only temporary results. However, there is increasing evi-
dence that genetic factors play an important role in the etiology of PD. 
For many decades several investigators reported family clustering of PD.J·4 Familial 
linkage studies and candidate gene studies have been carried out to investigate the role 
of genetic factors and the pattern of inheritance in PO, but d1e results arc controver-
sial,J,4 The ftrst evidence that PD can be inherited as a single gene defect came when a 
mutation in the a-synuclein gene was identified that caused PD in the Contursi kin-
dred, a large family with PD with an autosomal dominant inheritance pattern.-5 Since 
then, another mutation in a-synuclein/' a mutation in UCH-LP and two loci (2p13H 
and 4p14-16.3°) have been found in relation to autosomal dominantly inherited PD. 
Furthermore, a wide vatiety of mutations in the Parkin gene responsible for autosomal 
recessive juvenile parkinsonism (AR-JP) have been reported.HI,ll The PD genes re-
ported so far provide convincing evidence dut PO is a genetically heterogeneous disor-
der, yet they account for only a minority of familial cases OfPO.12-IS It is likely that sev-
eral other yet not identified gene~ are responsible for genetic susceptibility to PD. W/e 
therefore started a European collaborative study on affected siblings to further investi-
gate genetic factors in PD. The affected sib pail' (ASP) method does not need an as-
sumption about the mode of inheritance and is therefore an appropriate strategy for 
mapping genes of a complex disease trait such as PD.IG-IH The European Consortium 
on Genetic Susceptibility to Parkinson's Disease (GSPO), consisting of five clinical 
partners and four lab partners, was established in 1995 and aimed to recruit ASPs and 
large families with PO for a genome-wide .search for susceptibility genes in PD. 
The first analysis ,vas conducted on chromosomal regions that were of potential 
interest, because of earlier findings related to I'D with loci on 4q21-q23 (a-synuclein 
gene),' 4p14 (UCH-Ll gene),7 4p 14-16.3 (susceptibility locus)' and 21'13 (susceptibility 
locus)." \,Ie report here the overall design of the GSPD study as well as the results of 
the first genetic analyses on chromosome 2p, 4p and 4q. 
METHODS 
Families 
The GSPD-study, which is still ongoing, started in 1995 with the recruitment of fami-
lies with' PD and ,vas conducted in France, Germany, Italy, the Netherlands ,und the 
~;Hldy desiOIl of tho 1~,\JroP(-)tHI ASP study of hu'kinson's disHc-lse 
United Kingdom. Different established links and communication nehvorks were used 
to identify familles with at least two affected sibs \vith PD. In France, a net\vork of 
senior clinicians from 15 neurological departments of university hospitals was estab-
llshed to identify families with PD. In Germany families \vere ascertained through uni-
versity departments of Neurology and the German PD la), organisation. Tn Italy families 
were identified through a case control study of I'D in Naples, studies of familial PD in 
Rome, and a collaborative network of neurologists interested in PD from dle Italian 
Neurological Society, the Italian League against PD and t\vo patients organisations. In 
the Netherlands all neurologists were requested to notify affected families to the study 
centre in Rotterdam. In the UK all neurologists were relJ.uested to notify families with 
PD to the centre in London. [vioreover, the PD society (a lay organisation), the PD re-
search group (a nct\\'ork of clinicians interested in PD research) and the British Neu-
rological Surveillance Unit were asked to identify families. 
Ascertainl11ent and diagnostic procedures. 
In all countries the affected family lllembers were visited either at home or in a hospital 
for an inten,jew, blood sampllng and a clinical examination. This was done by a clini-
cian with experience in the diagnosis of PD, using a stanched protocol. All patients 
were videotaped according to a standard procedure. Any doubtful case was discussed 
\vith other reviewers experienced in the diagnosis of PD and a consensus agreed as to 
include or exclude the patients concerned. Patients and their affected relatives were 
included in the study if I'D was proven pathologically or if they met the following rig-
orous diagnostic criteria for clinically definite PD: (1) at least three out of four cardinal 
signs (bradykinesia, rigidity, resting tremor, asymmetry of signs at onset), and (2) at least 
a 30 ry(l improvement \'lith levodopa therapy, and (3) no exclusion ctiteria. Exclusion 
criteria wete: supranuclear palsy, pyramidal syndrome, cerebellar signs, dyspraxia, severe 
early loss of postural reflexc:-;, prominent early urinary symptoms, significant postural 
hypotension, a mini mental state cxalnination (i'vlMSE) score of less then 24/30 within 
t\vo years of onset, neuroleptic drug ingestion in the six months prior to onset, en-
cephalitis or possible toxic exposure in the six months pdor to onset. If the age of on-
set was younger then 40 years, \,\filson's disease Hnd other metabolic causes of parkin-
sonism had to be excluded too. Fr01n each participant, 30-ml venous blood \Vas sam-
pled for DNA extraction. In order to determine allele segregation in the families, \ve 
collected blood from parents and unaffected siblings, if available. If both parents were 
allYe, we did not collect blood samples from unaffected siblings. A sib was defined as 
unaffected if he or she did not show clinical characteristics compatible with PD. If one 
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parent was alive, we collected blood samples from this parent and two unaffected sib-
lingfi, If parents were not alive anymore, we collected blood from up to four unaffected 
siblings if available. All participants gave their informed consent according to the Dec-
laration of Helsinki for examination, videotaping, bloodsampling and genotyping. Eaeh 
partner obtained ethical approval for this project f1'0111 his or her institutional ethical 
committee. 
Datanlanagetnent 
Three databases \vere designed for accurate storage and transfer of data for appropriate 
data analyses. All clinical information is stored in a standatd database format, central-
ised in Paris (AD), that will allow the study of phenotype/genotype correlations. All 
core information on DNA-samples and family trees is stored in the central database in 
London (N\\f). Results of the genotyping are stored in the genotype database in Paris 
(J\flvl). This database is used to pertilfll1 the linkage analyses and to control inter-lab 
consistency. 
Genotyping 
Four partners from Paris (AB), l\Iunieh erG), Rotterdam (BA) and London (N\"') are 
participating in the laboratory \vork. At each lab centre and the Italian clinical centre, 
DNA was extracted fron1 venous blood samples using standard techniques and send to 
the repository in London. Wle analysed three regions on chromosome 2p, 4p and 4q in 
125 highl), informative families with ASPs using the markers D2S441, 2S2109, 
D2S1394, D4S2397, D4S391, D4S1609, D4S230, D4S405, D4S3350, D4S1647, 
D4S1578 and D4S2380 from the Gcnethon map for the genotyping. In all families 
DNA of parents or unaffected siblings v,ras available to determine allele segregation. 
Techniques for semi-automated DNA amplification using the polymerase chain reac-
tion and fluorescent oligonucleotides primers to analyse fragment sizes on an auto-
mated sequencer (ABI) were used for the genotyping. II).2o 
Data-analysis 
j\farker allele frequencies \vere set to their maximum likelihood values estimated in the 
data with the computer program \llTESSE.21 Painvise and multipoint model free link-
age analyses were conducted with the SIBPAIR" and the MLBGH2J·24 programs, re-
spectively, These. programs provide a likelihood-based test statistic for linkage which 
applies to the whole sibship of affected siblings. The painvise statistic is equivalent to 
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the LOD score calculated under the assumption of a simple recessive disease ll1ude1,25 
To test for linkage, the likelihoods over all families are maximised as a function of the 
rate of marker alleles IBD (y) among affected siblings, and the likelihood ratio test sta-
tistic is calculated against the null hypothesis of no linkage (y=O.5). The statistic follows 
a chi-square distribution with one degree of freedom (df) and can thus be expressed as 
a LOD scnre. 
RESULTS 
Up to the end of 1999, 246 families were recruited with familial PD. In total 43 families 
were excluded because one or both of the affected sibs did not (yet) fulfil our stringent 
criteria, mainly did not receive L-DOPA treatment. Another 27 families were excluded 
because they had mutations in the Parkin gene (unpublished data). A total of 176 ASP 
families fit the criteria for inclusion in the genome-\vide screen. The description of 
6milies and country of origin are presented in Table l. \,\Ie have 167 families with two 
affected siblings (167 ASP) and <) families with three affected siblings (27 ASPs), hence 
a total of 194 j\SPs out of 361 patients with PD. The clinical characteristics of all pa-
tients included in the GSPD study thus far are listed in Table 2. 
At present only two point LOD scores \vere available. l\{ultipoint LOD scores were 
not available due to uncertainties onn1arker location and order. 
Table 1 
Characteristics and origin of the sib pair families. 
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Germany 21 1 22 24 
France 59 2 61 65 
Italy 29 0 29 29 
Netherlands 26 2 28 32 
UK 32 4 36 44 
"fotal 9 176 ~~ ~~" 1'94 
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Table 2 
Clinical characteristics of the 366 patients with definite Parkinson's disease in 198 sib 
pairs 
Number of Affected sib pairs 
Number of patients 
Women: Men 
Mean age at onset in years (range) 
Mean disease duration in years (range) 
Clinical Signs 
- at onset Micrography (%) 
BradYkinesia (%) 
Tremor (%) 
Asymmetric Signs (%) 
- at examination Bradykinesia t%) 
Rigidity (%) 
Rest tremor (%) 
Urinary urgency (%) 
Urinary incontinence (%) 
UPORS off 
UPORS on 
Hoehn and Yahr 
MMSE 
- on treatment Improvement with levodopa (%) 
Mean daily dose of levadopa 
194 
361 
176:185 
57.9 ±11.2 (24-84) 
9.8 ± 6.7 (0-34) 
48 
73 
74 
76 
98 
95 
84 
30 
19 
48 ± 25 (n=73) 
29 ± 17 (n=282) 
2.8± 1.4 
25 ± 9 
59 ± 19 (30-100) 
560± 350 
Duration of levodopa treatment in months (years) 
Dyskinesias (%) 
85 (7) ± 86 (7) 
46 
UPDRS, Unified Parkinson's Disease Rating Scale; on, under treatment; off, without treatment; 
MMSE, Mini Mental State Examination 
Table 3 
Overall pairwise LOD scores. 
ehr 2p ehr.4p ehr 4q 
marker LOD score marker LOD score marker LOD score 
028441 0.09 0482397 0.06 0481647 0 
0282109 0.13 048391 0.05 0481578 0.006 
0281394 1.61 D481609 0.14 0482380 0 
048230 0.02 
048405 0.04 
0483350 0.012 
4H 
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The genotyping of the regions 2p, 4p and 4'1 in 125 families revealed one marker 
on ehr 2p, D2S1394, with a pairwise lod score, LOD=1.61 (nominal p-value=().(103). 
For the other markc," overall LOD scores were <0.14 (Table 3). \\Ihen the data were 
analysed for specific countries, the pau\vise linkage analysis sho\ved p-values smaller 
than 5% for marker D4S405 in German families (LOD= 1.22; p=O.OI), marker 
D2S1394 in German families (LOD=O.71; p=0.04) and British families (LOD=0.91; 
p=0.02) and marker D4S 1647 in Italian families (LOD=0.67; p=0.04). However, when 
these country specific results were adjusted for multiple comparisons (initial p-values 
adjusted by multiplying the p-values with the number of comparisons (n=6; one overall 
and five country specific comparisons)), no marker retained p-values smaller than 5%. 
DISCUSSION 
Thusfar, the European Consortium on GSPD has identified 194 strictly diagnosed 
ASPs \vithout kno\vn PD mutations. The initial screen on a highly informative subset 
of 125 families with ASPs regarding chromosomal regions 2p, 41', and 4'1 resulted in 
one marker, with a p-value smaller than 5 fl;(), providing weak evidence for linkage \vith 
Parkinson's disease. Although three markers produced initial p-vailles <0.05 in country 
specific analyses, the flndings did not reach significance at the level 5°;() after correction 
for multiple comparisons. 
The strengths of this ASP study include the systematic data collection \vith stan-
dardised documentation and videotaping of the affected individuals, the strict diagnos-
tic criteria that were used and the international ongoing collaboration through which we 
have collected and will continue to collect a large number of families with PD. An issue 
is whether we could have misclassified disease. Although a definite diagnosis of PO is 
based on neuropathological findings, we consider it unlikely that our results are biased 
because of misclassification of PD. Wie used very strict criteria to define our cases, with 
response to L-DOPA included as a major criterion and a review of any doubtful case 
by other experts. 
The ASP method is a yery appropriate approach to map genes in a complex disease 
trait as PD because it does not need an assumption about the mode of inheritance. A 
drawback, however, is that the power is usually lo\v, in particular for susceptibility loci 
\vith a low relative risk or low frequency of the tlsk allele. Because the mode of inheri-
tance of PD is unknown we cannot exactly estimate the statistical power of our study.26 
Hence, absence of linkage in our data may not be interpreted as excluding linkage. At 
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present we focussed on recessive models, but shortiy \ve vvill extend the analyses with-
out an assumption about the t110de of inheritance. 
Although the country-specific results did not reach significance at the level of 5% 
after correction for multiple comparison, v,re did S(Hne observations that merit further 
discussion. First, the D4S405 marker, which is closely localised to the UCH-Ll gene, 
showed some \veak evidence for linkage in German families. The mutation in the 
UCH-Ll gene that causes PD \vas origlnally detected in a German family.? Ho\vever, 
\ve did not fmd that specific ml.-.tation or any other mutations in tile coding regions of 
UCHL-I in our familics.!'.!5 Next, the D4S1647 marker, closely localised to the a-synu-
clcin (pARl<l), showed some evidence for Jinkage in Italian families. The first nlutation 
in the a-synuclein \vas also described in Italian families fr0111 the Contufsi kindred. 
However, mutations in the exons of the (j,-synuclein in these families 'vere not 
found. 12,1J Still, the D4S1647 marker remains interesting, since a polymorphism in the 
promoter region of the a-synuclein gene (NACP-Rep I), as well of the closely linked 
markers D4S1647 and D4S1628marker have been associated with PD.27 bIoreover, 
linkage disequilibrium between NACP-Repl and the D4S1647 marker was identified in 
PD cases, \vhich might include the presence of a susceptibility gene.27 
The only nlarker for which \ve found increased lod score in the overall analysis, 
D2S1394, is localised near to the PAlUO locus.' In their initial description of this lo-
cus, Gasser et al. did not find a significant maximum two-point LOD score for 
D2S1394, yet the marker was part of the haplotype segregating with two of their fami-
lies.s The fact that we found an initialnom1nal p-value of t)'04 in German families and 
that the initial locus was also detected in German families strengthens the role of the 
PARK310cus as a susceptibility factOl' for PD. 
\'(/e have successfully established a European Consortium and recruited a large 
number of affected sib pairs \vith PO for a genome wide search for susceptibility genes 
in PD. Our initial analyses did not reveal significant susceptibility regions on ehr 2p, 4p 
and 4q. 
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THE ILE93MET MUTATION IN THE 
UBUQUITIN CARBOXY -TERMINAL-
HYDROXYLASE-L1 GENE IS NOT OBSERVED 
IN EUROPEAN CASES WITH F ANnUAL 
P ARIZINSON'S DISEASE 
Abstract 
Recently an /le93Me! mutation in the ubiquitin-carboxy-terminal-hvdrolase-L 1 gene (UCH-
L 1) has been described in a German family with Parkinson's Disease (PO). The authors 
showed that this mutation is responsible for an impaired proteolytic activity of the UCH-
L 1 protein and may lead to an abnormal aggregation of proteins in the brain. In order to 
determine the importance of this or any other mutation in the coding region of the UCH-
L 1 gene in PO, we performed mutation analysis on Caucasian families with at least two 
affected sibs. We did not detect any mutations in the UCH-L 1 gene, however, we cannot 
exclude mutations in the regulatory or intronic regions of the UCH-L 1 gene since these 
regions were not sequenced. 
We conclude that the UCH-L 1 gene is not a major gene responsible for familial PO. 
INTRODUCTION 
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The 
prevalence of PD in Europe in subjects aged 55 years and older is 1.60,;',,',2 PD is char-
acterized by a progressive neuronal degeneration, which mainly affects the dopamincr-
gic neurons in the nigrostrlntal system but also other regions of tile brain.·\ The pres-
ence of intraneuronal inclusions, kno\vn as Lewy bodies in the pars compacta of the 
substantia nit,l""fa, is generally considered as the pathologic hallmark of PD, albeit not 
totally specific." The major clinical signs of the disease include resting tremor, bradyki-
nesia, rigidity and postural disturbances \vith a good response to treatment with levo-
dopa. The cause(s) of PD are stilllargcly unknown. In the vast majority, PO occurs in a 
sporadic fonn. However, in the last fev.' years there is increasing evidence that some 
forms of familial PD arc genetically determined,4-9 At present, it is generally accepted 
that PD is a genetically heterogeneous disorder. It is known that mutations in the u-
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synuclein gene are responsible for a small minority of autosomal dominant inherited 
PD7,R, whereas mutations in Parkin are responsible for some cases of autosoll1al reces-
sive inherited parkinsonism:-1-,(',9. Recently, a llussense mutation in the ubiquitin-carboxy-
terminal-hydrolase-Ll (UCH-L1) gene encoding for the UCH-L1 protein has been re-
ported in relation to PD. 10 The authors showed that this lle93Met mutation is respon-
sible for an, in vitro, partial loss of the catalytic thiol protease activity of the UCH-Ll 
protein, which may lead to aberrations in the proteolytic pathway and aggregation of 
proteins. lO This missense mutation \vas found in two affected sibs of a Gernlan family 
in \vluch hvo other members also were affected with PD. It wa:;; suggested that the dis-
ease appeared to be autosomal dominant with incomplete penetrance.w The gene for 
human UCH-L1 has been mapped to chromosome 4p14. 11 However, a large family 
\vith levodopa-responsive Lewy body parkinsonism, in \vhich a chromosome 4p14 
haplotype segregates with disease, has also been described. UCH-L1 was excluded as a 
candidate gene by both gene sequencing, for coding regions, and as a heterozygous 
coding varient (SIBi) in two affected individuals demonstrated expression of the gene 
from botll chr0111osomes.5 \'{Ie present here the results of mutation analysis on the 
complete coding region of the UCH-Ll gene in families widl PO, that were recruited as 
part of the study of the European Consortium on Genetic Susceptibility in Parkinson's 
disease. 12 All these families \vere previously te:;;ted for allele sharing on chromosome 4p 
(unpublished data). 
METHODS 
In this study, \ve only included European Caucasian families with PD. In all families, at 
least two affected sibs in each family were present. PD was diagnosed using the rigor-
ou:;; criteria of idiopathic PO according to a similar study design as has been described 
by lvfaraganore and co-workers.13 All patients gave their informed consent according to 
the Declaration of Helsinki. As part of the ongoing total genome screen in fanlilies with 
PD, up to present, 96 affected families \vith PO were tested for allele sharing on chro-
mosome 4p. The markers used to test for allele sharing on chr0111osome 4p are 
D4S230, D4S1609, D4S391, D4S2:l97, and D4S405, spanning 12.4cM tclomeric to 
centromeric on the Genethon J\fap. Since the family described by Leroy and col-
leagues \0 showed an apparent autosomal dominant (AD) inheritance pattern, only those 
families, that shc)\ved an inheritance pattern compatible \vith AD transmission, were 
eligible for mutation analysis for the UCH-L1 gene. Mutation analysis was performed 
on the complete coding l'egion of rile UCH-LJ gene in one randomly selected sjbling 
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Table 1 
Characteristics and origin of the individuals sequenced for the UCH·L 1 gene. 
number of individuals mean age of onset mean duration Origin of illness families sequenced years ISO) years ISO) 
French 4 4 57.019.3) 12.8114.5) 
German 51 18 
Italian 4 4 56.5 (7.3) 7.5 (5.8) 
Dutch 2 2 51 (12.71 10.5 (6.4) 
Table 2 
Primer sequences and PCR product size of the UCH-L 1 gene. 
exon primer forward (5' -3') reverse (3' ·5'1 product size (bpI 
1+2 Ex 1 + 2 CTCCCCCTGCACAGGCCTCA GTCCCTGCCAGCAGCCGGAA 353 
3 Ex 3 CTCCTCCCAGGCTCGGGT CTCAAGCTGGGGAGCGGC 307 
4 Ex 4 TGCACTCTCATTCTGAGATG GATGGGTGGCCTCTAAACCC 228 
5+6 Ex 5+6 AGGTTGCTCAGCATGTTCAG CAGTAGAAACACAGATGGC 364 
7 Ex 7 CTTAGTGGGCTTAGAATAGG AAGTGCCCTCATGAGAATAC 372 
8 Ex 8 ATCTAGGCTAGGTAAGCACG TGCTGGCTATACTGGAAGAG 271 
9 Ex 9 GGAGCCTTTCCCTATGTGAC ACCACATCCAAGGTCTTAAC 465 
from those families in which two affected siblings shared a haplotype for all 5 markers. 
The charactedstics and country of origin of the individuals tested for mutations in the 
UCH-Ll gene arc listed in Table 1. DNA was extracted from blood using standard 
techniques. All exons of the UCH-TJ gene, including flanking intronic sequences, were 
amplified from genomic DNA using specific primers. The seguences of the primers are 
shc)\vn in Table 2. The PCR reactions and product sequencing were done similarly to 
the study of Lincoln and co-workers.14 
RESULTS 
In total, 29 out of the 96 families showed an inheritance pattern compatible with auto-
somal dominant transmission. Of these 29 families, DNA of t 1 affected siblings was 
scquenced for mutations in the UCH-LJ gene because they shared a haplotype for ail 
five markers. The overall mean age at onset of PD was 55.2 years ± 8.1 years with a 
5!,) 
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mean duration of illness of 10,9 years ± 9.4 years, All individuals were analyzed for 
mutations in any coding region of the UCH-Ll gene. Pirst, \ve searched for the 
lle93Met alteration at nucleotide position 277 as described previously,'" We did not 
observe this mutation in the UCH-Ll gene in the 11 affected siblings that were se-
quenced. To further detect mutations in the UCH-LI gene we systematically performed 
sequence analysis of exons I to 9. Subsequently \ve identified the C54A variant in exon 
3 in one Dutch sibling and one Italian sibling. This creates a novel RsaI restriction site 
and is responsible for a serine to tyrosine substitution at codon 18 (SI8Y) (fable 2), 
The allele frequency we found fot' this polymorphism \vas somewhat lower as com-
pared to other studies.s.14 Tlus could easily be a chance finding since our sample size 
was relatively small, Alternatively the difference could be explained by the difference in 
genetic background with different allele frequencies. 
DISCUSSION 
The lack of the lle93illet mutation or any other mutations in the coding region of the 
UCH-Ll gene in our study population suggests that a mutation in the UCH-LI gene is 
not a major cause of familial PD in Europe. However, \ve cannot exclude mutations in 
the regulatory or intronic regions, as these regions were not sequenced. Since the 
prevalence of the Ile93J\Iet mutation is currently unknown and no mutations were 
found in 500 control individuals of different ethnic background"', it could be hypothe-
sized that the mutation found in the German family may be unique in this fanlily. Tlus 
explanation is supported by the fact that yet no other mutations in the UCH-Ll gene 
were found in the present study, wluch included German families. Although our results 
and very recently another report!4 do not support the involvement of the UCH-LI gene 
in the pathogenesis of PD, the malfunctioning of the ubi qui tin-dependent proteolytic 
system is known to be involved in the formation of intraneuronal inclusion bodies,1s.17 
Like a-syt1uclein, UCH-Ll is a constituent of Lewy bodies, It is thought to playa role 
in the cleavage of polymeric ubiquitin into Inonomers and may as well hydrolyze C-
tenninal esters and anudes of ubiquitin. 18 Lewy bodies are strongly ubiquitinated and 
immunoreactive \vith neum-specific ubiquitin carboxy terminal hydrolase and some 
subunits of the 26S proteasome. The reports of mutations in the a-synuclein gene7,8 
and the observation that a-synuclein is a major component of Le\vy bodies!'} bas accel-
erated research in Lew), body formation and deposition. Alpha-synuc1ein antibotlies 
have enabled novel, occult pathology to be described in both neurites in idiopathic PD 
and glia in multiple system atrophy (MSA) II 9,20]. Recently, another gene-defect, ini-
5G 
tially described in Jnpan and associated with an autosomal recessive juvenile parkinson-
ism (AR-JP), has been mapped to chromosome 6q25.2-q27.' i\{utations in this gene, 
named Pnrkin, have now also been reported in European and Algerian familics. 4,'J The 
similarity of the Parkin protein(' to the ubi'iuitin protein family suggests that the ubiq-
uitin-dependent proteolytic system may play an important role in the pathogenesis of 
PO, but the lack of Le,,~' bodies in AR-JP suggests that not only Le"T body formation 
but also other factors involved in neurodegeneration like oxidative stress and specific 
neurotoxins may be involved in the pathogenesis of PD. At present, it is generally ac-
cepted that a genetic contribution in the etiology to PD is of major importance and 
therefore research should be focussed on other yet unidentified susceptibility genes in 
PD. 
We conclude that the UCH-U gene is not a major gene responsible for familial 
PD. 
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A WIDE VARIETY OF MUTATIONS 
IN THE PARKIN GENE IS RESPONSIBLE FOR 
AUTOSOJ\tIAL RECESSIVE PARKINSONISM IN 
EUROPE 
Abstract 
Autosomal recessive juvenile parkinsonism (AR-JP, PARK2, OMIM 602544), one of the 
monogenic forms of Parkinson's Disease (PO), was initially described in Japan. It is char-
acterized by early onset (before age 40), marked response to levodopa treatment, and 
levodopa induced dyskines;as. The gene responsible for AR-JP was recently identified 
and designated parkin. We have analyzed the 12 coding exons of the parkin gene in 35 
mostly European families with early onset autosomal recessive parkinsonism. In one fam-
i/y, a homozygous deletion of exon 4 could be demonstrated. By direct sequencing of the 
exons in the index patients of the remaining 34 families, eight previously undescribed 
point mutations (homozygous or heterozygous) were detected in eight families that in-
cluded 20 patients. The mutations segregated with the disease in the families and were 
not detected on 110 to 166 control chromosomes. Four mutations caused truncation of 
the parkin protein. Three were frameshifts (202-203deIAG, 255de1A, 321-322insGT) and 
one a nonsense mutation (Trp453Stop). The other four were missense mutations 
(LysI61Asn, Arg256Cys, Arg275Trp, Thr415Asn) that probably affect amino acids that 
are important for the function of the parkin protein, since they result in the same pheno-
type as truncating mutations or homozygous exon deletions. Mean age at onset was 
38 ± 12 years, but onset up to age 58 was observed. Mutations in the parkin gene are 
therefore not invariably associated with early onset parkinsonism. In many patients, the 
phenotype is indistinguishable from that of idiopathic PD. This study has shown that a 
wide variety of different mutations in the parkin gene is a common cause of autosomal 
recessive parkinsonism in Europe, and that different types of point mutations seem to be 
more frequently responsible for the disease phenotype than are deletions. 
INTRODUCTION 
Parkin1\on>s Di1\case (PO) is a frequcnt ncurodegcnerativc disorder ,vith 'J prevalence 
close to 2% after age 65. 1 The major signs of the disea1\c are trcmor, rigidity and brady-
kinesia associated with a good response to treatment \vith levoJopa. The disorder is 
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caused by a massive loss of dopaminergic neurons in the pars compacta of the substan-
tia nigra. The etiology of the disease is still unknown, but the existence of genetic sus-
ceptibility tactors is strongly suspected,2 Several familial forms of PD ''lith autosomal 
dominant transmission have been reported. rvlutations in the a.-synuclein gene on 
chromosome 4q21-q23 \vere described in several PD families with early onset -and rapid 
disease progression.3,4 However, a.-synuclein is a minor locus, found only in a subset of 
families \vith dominant transmission.s.7 t\ second susceptibility locus \vas localized on 
chromosome 2p13 in German families with autosomal dominant PD.!! A parldnsonian 
syndrome with autosomal recessive transmission (AR-JP, PAlua, Oi'lHM 602544) was 
first described in Japan.',!(' AR-JP patients show the typical signs of PD, but they are 
associated with: i) early onset, typically before the age of 40; ii) dystonia at onset; ill) 
diurnal fluchmtions; iv) slow disease progression; v) early and severe levodopa induced 
dysldnesias, In a few cases, neuropathological examination has shown a massive loss of 
dopaminergic neurons in the pars compacta of the substantia nigra, but the absence of 
Le\\1' bodies, the histopathological hallmark of pD,',ll,12 Recently, the AR-JP locus, 
designated PARla, was mapped to chromosome 6q25,2-27 in consanguineous Japan-
ese families.13 Subsequently, linkage analyses, our own14 and others'l-\ have demon-
strated the existence of non-Japanese PARla families in Europe, the United States and 
the l\'liddlc East. Homozygous deletions of one or more micro satellite markers in 3 AR-
JP families greatly reduced the initial 17 eM candidate interval.
'
4-II, Very recently, Kitada 
et a!. identified a novel gene, designated pmkin, in which homozygous deletions of ei-
ther exon 4 or 3-7 ,vere detected in four Japanese families with AR-JP.17 The parkin 
gene has an estimated genomic size of 500 kb and consists of 12 coding exons with an 
open reading frame of 1395 bp, The corresponding protein, parkin, composed of 465 
amino acids, shows moderate h0111010gy to ubiquitin at the amino terminus and con-
tains a lUNG-finger motif at the carboxy terminus. 17 Subsequently, homozygous dele-
tions of exon 3 were found in t\vo European fammes and of exon 8-9 in one Algerian 
family.18 To date, t\vo point mutations in the parkin gene have been reported in t\'lO 
Turkish AR-JP families.'" 
In order to determine the frequency and the diversity of mutations in the parkin 
gene as a cause for the AR-JP phenotype in Europe, we amplified tl,e 12 coding exons 
of the parkin gene in 35 families with autosomal recessive early onset parkinsonism and 
sequenced the exons in tl,e patients that did not show homozygous exon deletions, 
GO 
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RESULTS 
A new family with an exon 4 deletion 
A homozygous deletion of exon 4 was detected in all 3 patients of an Italian family (IT-
005), previously shown to be homozygous for four markers at the disease IOCUS l4 
(figure 1). 
Point mutations in the parkin gene 
Tn the index patients from the 34 families that did not sho\v homozygous exon dele-
tions, sequence analysis of all coding exons, including the exon intron boundaries, re-
vealed 11 sequence variations in exons and 3 in introns (table 1). Eight of the exoruc 
variations cosegregated \vith the disorder in the families (figures 2) and \vere not de-
tected in 110 to 166 control chromosomes (table I). They are therefore most probably 
causative n1utations (figure 3). 
Pour mutations resulted in truncated proteins: 202-203deIAG in exon 2 of families 
TT-020 and UK-086, 255dclA in exon 2 of family PR-096, 321-322insGT in exon 3 of 
family FR-119, and 1459G>A (Trp453Stop) in exon 12 of family IT-006. These muta-
tions were homozygous in patients, except for the 202-203delAG 111utation in families 
IT-020 and UK-086. 
Four missense mutations were observed: In family IT-020, a heterozygous 584A>T 
transversion (LysI6IAsn) in exon 4 was detected in addition to the 202-203deIAG 
Inutation described above. Segregation analysis showed that the two Inutations \vere 
located on different alleles, and that all patients \vere compound heterozygotes (figure 
2). Two other heterozygous, non-conservative amino acid changes were observed in 
exon 7 of patients from families DE-012 and IT-015: 867C>T (Arg256Cys) and 
924C>T (Arg275Trp), respectively. Finally, a homozygous 1345C>A transversion in 
exon II of all patients from family IT-014 resulted in a conservative (Thr415Asn) 
anuno acid change. 
In three of the families with heterozygous mutations (UK-086, DE-OI2,IT-OIS), no 
complementary heterozygous mutation could be detected by sequencing. 
Polymorphisms 
Three of the 11 exonic sequence variations were detected in control chro1110so111es, and 
wer.e tl1\ls dassified as polymorphisms (table I). They resulted in two conservative and 
one 110n conservative amino acid change. A 601G>A transition (Ser167Asn) \vas het-
G1 
Table 1 
Variants of the parkin gene 
amino acid change! f technique of expected fragment length number 
nucleotide change position of the type ~ of control freque~cy of 
d mutation detection in bp the varrant stop co on cases 
exonic 
Ex2 202-203de1AG Gln34IStop37 frameshift PAGE WT: 308 55 0% 
V: 306 
Ex2 255delA Asn521Stop81 frameshift Fok I WT: 278+30 83 0% 
creation of site V: 222+57+30 
Ex3 321-322insGT Trp741Stop81 frameshift ASO 83 0% 
Ex4 584A>T Lys161Asn missense ASO 83 0% 
~x4 601G>A Ser167Asn missense AlwN I WT: 164+97 83 1% 
loss of site V: 261 
I!x7 867C>T Arg256Cys missense ASO 83 0% 
Ex7 924C>T Arg275Trp missense Sau3A I WT: 142+97 83 0% 
loss of site V: 239 
Ex10 1239G>C Val380Leu missense ASO 45 16% 
Ex11 1281G>A Asp394Asn missense Tao I WT: 221+84 90 7% 
loss of site V: 303 
Ex11 1345C>A Thr415Asn missense ASO 83 0% 
Ex12 1459G>A Trp453Stop nonsense Nla IV WT: 142+17+35+61 83 0% 
loss of site V: 159+35+61 
i(1tronic 
[;htron2 IVS2+25T>C BstN I WT: 308 bp 45 19% 
creation of site V: 264+44 bp 
Irtron3 IVS3-20C>T Mnll WT: 201 +60 45 10% 
loss of site V: 261 
rntron7 IVS7-35A>G Mae 111 WT: 206 36 27% 
creation of site V: 159+47 
The nucleotide numbers are given according to the cDNA sequence published in the DNA Data Bank of Japan {DDBJ; accession number: 
.£:0.8009973); PAGE = polyacrylamide gel electrophoresis; ASO =:: allele specific oligonucleotide; causative mutations are given in boldwfaced italics. 
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Figure 1 
Homozygous exon 4 deletion in the 
patients of the Italian family IT-005, 
Bands (peR products of the indi-
cated exons) correspond to the 
numbered individuals. Black squares 
(men) and circles (women) repre-
sent affected individuals. Age at 
onset (in years) is given above the 
patient's symbol. Slashed symbols 
indicate deceased individuals. 
Ex =: exon, i = inner, 0 = outer. 
erozygous in only one of the t\vo affected members of family FR-730 and on 1(0) of 
the control chromosomes (2/166), In addition, it was found in all sibs, including an 
unaffected, of family IT-020, in which the disease is already explained by the compound 
heterozygosity of t\vo causative mutations (see above). 1\ 1239G>C transversion 
(VaI380Leu) in exon 10 was either heterozygous or homozygous in 11 families (IT-014, 
IT-020, IT-OSS, FR-OI7, F1<029, PR-038, FR-096, FR-431,UK-006, UK-086, DE-022), 
It did not segregate with the disease and was found on 16°;«> of control chr0111oso111es. 
A 1281G>A transition (causing the non conservative Asp394Asn change) in exon II 
was heterozygous in the index patient of family UK.-046 a11d heterozygous or h01110zy-
gous on 7%1 of control chromosomes. 
Variants in intrans 2, 3 and 7 (IVS2+25T>C, IVS3-20C>T, IVS7-35A>G), were 
located at distance frOlll the splice sites. These polymorphisms \vere detected on C011-
trol chromosomes at a frequency of 19°;;" 10% and 27(Yo, respectively (table I), Finally, 
a homozygous 768C>T transition (pro223Ser) was found in all individuals sequenced, 
suggesting that 768C was an error in the initial cDNA sequence,17 
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Figure 2 Ileft) 
Families with point mutations in the parkin gene. Complete cosegregation of the muta-
tion with the disease is shown. Black squares (men) and circles (women) represent af-
fected individuals with age at onset (in years) indicated above the patient's symbol. 
Slashed symbols indicate deceased individuals. The numbers of unaffected sibs not 
analyzed are given in diamonds. For each mutation the genotype of the family member is 
indicated (+ / + = homozygous wild type, + /- = heterozygous for the mutation, -/-
homozygous for the mutation). Under each genotype, the detection data are shown. 
PAGE: electrophoregrams with allele sizes in bp. ASO: autoradiograms of mutated and 
wild type allele. Restriction assay: PCR products after digestion with the appropriate 
restriction enzyme. Fragment lengths in bp are indicated. Mut = mutated; nd = age at 
onset not determined, as patient is unaware of her clinical signs. 
Functional dotllains of the parkin protein 
According to the PROSITE program, the conservative amino acid change Thr415Asn 
is located \vitllln the consensus sequence for putative phosphorylation sites of cAt\lP-
and cGlvfP-dcpcndcnt protein kinases (KKTI) and protein kinase C (IIK). The trun-
cating nonsense mutation Trp453Stop is located within a putative N-myristoylation site 
(GCEWNR). 
Tnmcating Illutations 
255deiA 
'O":~3deIA~G ~ 3r'21nSGT 
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Figure 3 
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Point mutations in the parkin gene. The coding sequence of the gene with its 12 exons is 
represented as a bar. Exons are numbered 1 to 12. The eight causative point mutations 
are positioned according to their effect on the protein (truncating versus missense). The 
ubiquitin-like domain and the RING finger motif are hatched. For the mutations Thr415Asn 
and Trp453Stop the putative phosphorylation sites (PI and the N-myristoylation site 1M), 
respectively, are indicated. UTR = untranslated region. 
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Table 2 
Clinical characteristics of 31 patients from 12 Parkin families according to the type of mutation 
Deletion Truncating Missense Total 
families {patients) 4 (11) 4 (9) 4(11 ) 12 (31) 
; 
~ean age at onset (range) 33.9 ± 16.3 (7·58) 38.2 ± 8.0 (27·53) 42.5 ± 8.5 (30·56) 38.1 ± 12.1 (7·58) 
lII1ean disease duration (range) 14.8 ± 6.5 (3·26) 16.3 ± 9.4 (4·29) 16.3 ± 8.9 (0.5·31) 15.8 ± 8.0 (0.5·31) 
~oehn and Yahr score 3.4 ± 1.1 2.2 ± 0.9 2.8 ± 0.9 2.8 ± 1.0 , 
Bradykinesia 
i 
11/11 8/9 11/11 97% 
~igidity 10/11 9/9 11/11 97% 
Tremor 6/11 8/9 7/11 68% 
lPystonia at onset 6/11 1/7 0/5 30% 
Good response to levodopa (de novo cases) 10/10 (1) 9/9 9/9 (2) 100% 
~yskjnesia 6/10 4/9 8/9 71 % 
fluctuations 5/10 3/6 ND 50% 
erisk reflexes lower limbs 4/11 0/6 3/4 33% 
Parkin none mutCltions in An-JP 
Genotype/phenotype correlations 
Point mutations were present in eight families, tI,at included 20 patients (table 2). The 
patients of family IT-020 \vith a truncating mutation on one allele and a mi::\sense mu-
tation on the other allele were classified in the nus sense mutation group, assuming that 
missense mutations nlay be less deleterious if they result in only partial loss of function 
of the parkin protein, thereby determining the severity of ti,e illness. Accordingly, the 
patients of the fanulies for whom only one heterozygous mutation could be detected 
were included among the truncating (UK-086) or missense mutations (DE-012, IT-
015). 
The II patients with homozygous exon deletions of the plll'kill gene (3 previously 
published families IS and family IT-ODS), the II patients with missense mutations (4 
families) and the 9 patients with tlUncating mutations (4 familie::\), showed an overall 
phenotype of early onset parkinsonism (table 2). J\lean age at onset was 38±12, ranging 
from 7 to 58. Parkinsonian rigidity (97%) and bradykinesia (97%) were almost always 
present, \vhereas tremor was observed in only 680ft). These features \vere associated \vith 
dystonia at onset in 30 lYo and \vith brisk reflexes in the lower limbs without a Babinski 
sign in 33%1. After a mean disease duration of 16±8 years, dyskinesias and fluctuations 
were present in 71 o/u and 50 tYrI, respectively. The effect of the mutations on age at onset, 
severity or fre'luency of signs did not differ significantly among the patients carrying 
different types of mutations. 
DISCUSSION 
The initial report of Kitada et al. describing homozygous deletions of exon 4 or 3-7 in 4 
Japanese fa1nilicsl7, our own observation of homozygous deletions of exon 3 or 8-9 in 
hvo European and one Algerian familyl8, and the newly identified exon 4 deletion in an 
Italian family sho\v that a variety of deletions in the parkin gene can cause autosomal 
recessive parkinsonism, with age at onset as late as 58, as observed in the Italian family 
IT-ODS (figure I). However, is was suspected tI,at other types of mutations (e.g. point 
l1lutations) might be a more common cause of the discase. 1H The only point tl1utations 
reported to date wefe hvo homozygous single base pair substitutions in two consan-
guineous Turkish families, whieh resulted in a Thl'240Al'g llli"ense mutation in exon 6 
and an Ala311Stop nonsense mutation in exon 8. Until now, however, it could not be 
deternuned whether point mutations in the parki" gene account for a significant pro-
portion of autos01l1al recessive eady onset parkinsonism. 
(;7 
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Taken together, our 3 families with previously reported exon deletiotlslH and the 9 
families with mutations detected in the present study demonstrate that mutations in the 
ptllkiJl gene are the cause of the disease in approximately 30lYo of the families '.vith auto-
somal recessive parkinsonism analyzed (12/38), including 11/35 from Europe. Point 
mutations were detected in 2/3 of OUl' families (8 of 12 families) and thus seem to be 
more frequent than homozygous exon deletions (4 of 12 families). 
The fact d,at a second mutation could not be detected in families OR-012, IT-0l5 
and UI<-086 (,vhich were heterozygous fo1' only one mutation) suggests the presence of 
a complementary mutation that could not be detected by the techniques used in this 
study. This second mutation might be located in regions of d1e gene that were not se-
quenced (e.g. the promotor region) or might be present as a heterozygous exon deletion 
that can not be analyzed by simple peR amplification. However, in order to estimate 
the frequency of compound heterozygotes resulting from the combination of a point 
mutation and an exon deletion or of two different exon deletions, we cOJnpared the 
frequencies of the homozygous exon deletions (n=4) and the homozygous point tnuta-
tions (n=4) in 8 families ,vith known 01' suspected consanguinity. The frequency for the 
t\vo types of homozygous mutations was 50% each in tills sample. The frequency of 
compound heterozygotes for each of the two combinations (deletion + point mutation 
or deletion + deletion) could therefore reach up to 25')'0. However, the small sample 
size precludes accurate estimation of these frequencies. 
Only one of the point mutations, the 202-203delAG frameshift, was found in two 
families of different origins (Italy and UK), suggesting that the mutation occurred inde-
pendently. Although the patients from these families shared two frequent alleles for the 
PARK2-markers D6S411 (allele 2 = 59%) and 06S1550 (allele 2 = 68%), tl,e alleles for 
two other tightly linked markers, 06S305 and D6S1579, were different (data not 
shown), indicating that a recent common founder effect is unlikely. 
All the point mutations are novel and show that a wide variety of different muta-
tions in the parki!l gene can account fot' the disease. The pathogenic role of the point 
mutations was shown by: i) co segregation of the mutations ,vith the disorder in the 
families and ll) their absence in a large number of control chromosomes (1'10 to 166 
depending on the mutation). 1\11 the point mutations identified are likel), to have major 
functional consequences. The foUl' truncating mutations (202-203delAG, 255delA, 321-
322insGT and Trp453Stop), which were detected in homozygous state in 3 of 5 fami-
lies, clearly cause a loss of function of the parkin protein, compatible with the recessive 
tHode of inheritance. Three of the missense mutations result in non conservative atnino 
acid changes (LysI6IAsn, Arg256Cys and Arg275Trp). In fanuly IT-020, the 202-
203delAG frameshift mutation on one allele, \vlllch already results in a loss of function, 
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is associated with an apparently deleterious Lys161Asn nussense mutation on the other 
allele. The conservative Thr415Asn amino acid change, that involves neutral amino 
acids with different polar side chains, homozygous in all five patients of family IT-OI4, 
is located within two consensus sequences of different protein kinases (cAi\'fP- and 
cG1IP-dependent protein kinases and protein kinase C), and might alter post-transla-
tional modifications. In addition, codon 415 is located very close to the first cysteine of 
the lUNG-finger motif (codon 418) and could affect its structure. 
The mutations, ",rhich had different effects on the parkin protein, were distrIbuted 
over 6 exons, excluding a mutational hot spot. It is interesting to note that, in contrast 
to the reported Gln311Stop mutation PJ, the truncating point mutations identified in dus 
study correspond to the N- and C-terminal regions of the parkin protein (ubiquitin-like 
and RING-finger motif, respectively), whereas d1e missense mutations affect the more 
central regions of the protein, as docs the Thr240Arg mutation. I'} The previously de-
scribed ubiquitin-like and RING-finger domains ",rere not affected by the nus sense 
lnutations. The carboxy terminal region appears to be extremely important since a ho-
n1ozygous Trp453Stop nonsense mutation, which only removes the last 12 carboxy 
terminal residues, causes the disease, perhaps by altering a N-myristoylation site be-
tween codons 450-455, that prevents a necessary post-translational modification of the 
protein. The absence of significant clinical differences in this study among the patients 
with different types of mutations suggests that the modifled amino acids arc all of 
functional itnportance and d1at their replacement, like the truncating mutations} causes 
loss of function. The location of the mutations may therefore point to unknown tlH1C-
tional domains. 
The phenotype of the families ''lith point mutations in the parkin gene and those 
with exon deletions covered a clinical spectrum that was broader than in the Japanese 
families originally described 17.'", and is often vel')' close to that of idiopathic PD (table 
2). J\{ean age at onset, 38, was that of early onset PD. In 13 patients, however, onset 
occurred after age 40. Dystonia or brisk reflexes were less frequent than previously re-
ported."'.'" Overall, the phenot),pes of patients classified according to the effect of the 
mutations on the parkin protein \vere si1nilar, although the earlier ages at onset, 7 to 18 
years, were observed in the Algerian family with deletion of exons 8 and 9. 18 Similarly 
earl)' onset was also observed in the Japanese family with deletion of exon 3-7 (17) as 
,vell as in the patient with d1e Gln311Stop mutation l9, raising the question of the func-
tional consequences of exon deletions and truncating events in specific regions of the 
parkin protein, especially as onset within our patients group with truncating n1utations 
was later (between 27 and 53 ),ears). 
Finally, three exonic variants (Scr167Asn, Val380Leu and Asp394Asn) were classi-
fied as polpl1orphisms, since they were detected at different frequencies (between 1 and 
16 %) on control chromosomes. In $0111C families, they did not segregate with the dis-
ease. Furthermore, they were found in a family in which the disease ,vas explained by 
other mutations (the polymorphism Serl67 Asn in family IT-020) or were homozygous 
in healthy controls (Va1380Leu and Asp394Asn). They arc therefore insufficient to 
cause the disease by themselves. They might, hO'VCVCf, alter the function of the parkin 
protein and contribute to the pathogenesis of idiopathic Parkinson's Disease. Associa-
tion studies will help to clarify this question. 
In conclusion, this study shows that point ll1utations in the pm-kin gene are a com-
1110n cause of autosomal recessive parkinsonism in Europe and seen1 to be more fre-
quent than the exon deletions :;;0 far described. Furthermore, the mutations in the par-
ki/J gene are associated with a wide range of ages at onset as weJI as of clinical si6ms and 
can result in familial parkinsonism clinically indistinguishable from idiopathic Parkin-
son's Disease. The mutations detected are diverse in their effects on the parkin protein 
as ,veil as in their localization within the gene. The diversity of the mutations and the 
absence of a mutational hot spot will complicate 1110lecular diagnosis, but the evident 
il11portance of the amino acids affected will help to analyze the function, still unkno,vn, 
of the parkin protein. 
MATERIALS AND METHODS 
Patients and statistical analysis 
Thirty-eight families were selected according to the following criteria: i) presence of 
parkinsonism with good response to levodopa (2: 30%1 improvement) in at least 2 sib-
lings, and absence of excluding criteria sllch as extensor plantar reflexes, ophthahll0ple-
gia, early (after 2 years of disease evolution) dementia or autonomic failure; ii) onset .:s 
45 years in at least one of the siblings; ill) inheritance compatible with autosomal reces-
sive transmission (several patients in a single generation with or \vithout known con-
sanguinity). The families originated from France (n=12), Italy (n=IO), Germany (n=7), 
Great Britain (n=4), Algeria (n=I), J\{oroeco (n=I), The Netherlands (n=I), Portugal 
(n= I), Vietnam (n= I). FoUl' families from Algeria, France, Italy and Portugal were ex-
cluded from sequence analysis because they were found to carry homozygous deletions 
of either exons 3 01' 8-9 (18) or exon 4 (family IT-OOS). 
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The patients and unaffected relatives \vere examined by us in one of the movement 
disorder clinics of the European Consortium on Genetic Susceptibility in Parkinson's 
Disease (GSPD) or the French Parkinson's Disease Genetics Study Group, according 
to a standardized protocol using the same inclusion and exclusion criteria. All patients 
were videotaped and the clinical data were centralized. The Kruskal-Wallis test was used 
for comparisons of means, and the X2 test for comparison of frequencies (Yates cor-
rected). Blood samples were taken with infonned consent from the patients and their 
first degree relatives. 
peR amplification and sequence analysis 
The 12 coding exons of the parkiN gene fr01n 35 index patients were amplified from 
genomic DNA by PCR as described by Kitada et al." In family 11'-005, an additional 
pair of exonic primers was used for exon 3 (Ex3iFor (S'-AATTGTGACCTGGATCA-
GC3') and Ex3iRev (5'-CTGGACTTCCAGCTGGTGGTGAG-3')). For exons 4 and 
7 only the intronic primer pairs were used. The same primers were used for the sequen-
cing of the PCR products of the 12 exons on both strands using the "Big Dye Termina-
tor Cycle Sequencing Read), Reaction" DNA Sequencing Kit (ABI PRISM), according 
to the manufacturer's recommendations, on an ABI 377 automated sequencer with the 
"Sequence Analysis 3.0" (ABI PRISi'd) software. 
Each tiine a nucleotide variant was identified in an index case, its cosegregation 
\vith the disease was established in the patient's family, and its frequency was deter-
mined in 36 to 90 controls (with or without other neurological diseases). Three differ-
ent techniques were used to detect mutations in the peR products corresponding to the 
different exons: i) allele specific oligonucleotides (ASO) to detect the wild type and the 
variant sequence; ii) digestion \vith the appropriate restriction endonuclease, ill) poly-
acrylamide gel electrophoresis (table 1). Nucleotide positions \vere determined accord-
ing to the eDNA sequence published in the DNA Data Bank of Japan (DDB); acces-
sion number: AB009973). 
ASO 
'Ten microliter of the peR product \vere blotted onto Hybond N+ nylon mClllbrancs 
(Amersham) after denaturation at 95°C for ,'i min and fixed in a microwave oven at 
600W for 2 min. For exon 3, the primers Ex3iFor and Ex3iRev were used. The oligo-
nucleotides (table 3), labeled with dCTp32 using the Terminal Transferase Kit 
(Boehringer Mannheim), were hybridized to the membrane at 44°C overnight in a 
buffer consisting of ,'iX SSPE, 5X Denhardts and 0,1% SDS. The membranes were 
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Table 3 
Oligonucleotides used for the ASO technique 
location nucleotide change oligonucleotide sequence 
Ex3 321-322insGT WT: 5'-TGCAGAGACC::GTGGAGAAAA-3' 
V: 5'-GCAGAGACCGTGTGGAGAAA-3' 
Ex4 584A> T WT: 5'-GCCGGGAAA~CTCAGGGTA-3' 
V: 5'-GCCGGGAAAICTCAGGGTA-3' 
Ex7 867C>T WT: 5'-TGCAACTCCfGCCACGTGA-3' 
V: 5'-TGCAACTCCIGCCACGTGA-3' 
ExlO 1239G>C WT: 5'-TGCAGTGCCgTATTTGAAG-3' 
V: 5'- TGCAGTGCCfTATTTGAAG-3' 
Exll 1345C>A WT: 5' -AGAAAACCAfCAAGCCCTG-3' 
V: 5' -AGAAAACCA~CAAGCCCTG-3' 
The nucleotide change in the oligonucleotides is represented in bold and underlined; WT ;::: wild 
type, V = variant 
washed twice for 30 min in 2X SSC at 59°C and exposed to lIIP film (Amersham) for 
3-6 hours. 
Restriction assay 
fifteen ~ll of peR product were dige~ted with re~triction enzyme~ according to the 
manufacturer's recommendation~. The expected fragment lengths are given in table 1. 
Polyacrylamide gel electrophoresis 
A 5'-fluorescent (Hex) !(l1'\vard primer (Kitada et al.") was used to amplify cxon 2. The 
presence of the 202-203delAG variant, resulting in a shorter PCR product (306 versus 
308 bp), was establishcd by fragment size measurement using an ABl 377 automated 
sel}uencer \'lith the "Genescan 2.0.2" and "Genotyper 1.1.1" ~oft\Vare (ABI PRIS[vI). 
Detertllination of additional functional domains in the parkin protein 
The internet web site PROSITE (http://expas),.hcuge.ch/cgi-bin/scanprosite) was 
used to determine additional functional domain~ of the parkin protein. 
I'arkin wnw nlutations in AH"JP 
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General discussion 
Ii N THIS THESIS several studies concerning the genetic susceptibility to Parkinson's • disease (PO) are described. We studied possible genetic causes of PO in two differ-
. ent settings, a population-based cohort study and an affected sib pair study, using 
different approaches, including aggregation, association, and linkage sib pail' analysis. In 
this chapter, after briefly summarizing our main findings, \ve will discuss senne of the 
general and specific methodological issues that pertained to these studies and \ve will 
discuss the definition of the outcome used in our studies. Furthermore, we will discuss 
how the identification of genetic factors for PO may further our understanding in the 
etiology of tills disease. Pinaliy, we will discuss possibilities of future epidemiological 
research regarding the etiology of PD. 
BACKGROUND 
Up to present several hypotheses have been postulated in the etiology of PD, however 
the causes of PD still largely remain unknown. Over the last two Cenhlr1eS prevailing 
thinking about the etiology of PD alternated continuously between genetic and envi-
rOlllnental hypotheses. IvIore than a century ago, Go\versl observed that 15% of pa-
tients \vith PO did have a positive family history, and thus emphasized the importance 
of inheritance in the etiology of PD. In the carll' 20;h century a possible infectious etiol-
ogy, became more popular. In the last decades several investigators reported familial 
aggregation of PD.2-4 The hypothesis of environmental factors in PD was favored in 
the early nineteen eightiess and the genetic hypothesis regained strong attention in the 
nineteen nineties. The identifications of genetic defects in families with PD \vith an 
autosomal dominant inheritance pattern(,·H or with an autosomal recessive inheritance 
pattern'J,1O and the reports of hvo other lad in families with PDll,12 stressed dle impor-
Table 1 
Chromosomal location of genes and loci related to Parkinson's Disease (PO) or subtypes 
of PD with the specific mode of inheritance. 
Gene 
a-synuclein 
Parkin 
UCH-L 1 
Unknown 
First report 
Polymeropoulosetal. 1997 
Kitada et al 1997 
Leroy et al. 1998 
Gasser et al. 1998 
Chromosomal 
location 
4q21-q23 
6q25.2-q27 
4p14 
2p13 
4p14-16.3 
Mode of inheritance 
Autosomal 'dominant 
Autosomal recessive 
Autosomal dominant 
Autosomal dominant 
Autosomal dominant 
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tance of genetic factors in the etiology of PO or subtypes of PD. The chromosomal 
location of these genes and loci together with the mode of inheritance are listed in Ta-
ble 1. These observations provide convincing evidence that PD is genetically heteroge-
neous, Although genes like a.-synuclein,7,8 UCH-LU' and Parkin<),l0 can cause PD, they 
account for a smallminorlty of patients with PD. The aim of the work presented in this 
thesis was to obtain more insight in the role of known and other yet unidentified ge-
netic factors in the occurrence of PD. 
MAIN FINDINGS 
Familial aggregation study 
We prospectively studied the risk of PO among participants from the Rotterdam Study 
with a family history of PO and compared it to those without such a history (chapter 2). 
We found that individuals with a positive lamily histOlY of PO, in particular with at 
least t\vo participants with PD, did have an increased risk of PD, suggesting that genetic 
factors may playa role in the cause of PO in the elderly. 
Genetic association studies 
We investigated the role of three candidate genes in PO within the Rotterdam Study 
(chapter 3). The first two candidate genes, N-acetyltransferase-2 (NAT-2) and cyto-
chrome 1'-450 debrisoquine hydroxylase (C\'P206), thought to be involved in the me-
tabolism of neurotoxins, have been associated with PD,D,14 In our study, both genes 
were not associated with PD suggesting that these genes are not likely to play an im-
portant role in the etiology of PO in the Rotterdam Study. Moreover, we studied the 
role of the APOE gene in PO and found that in the elderly the APOE 82-allcle in-
creases the risk of PD and in particular the risk of PD \vith dementia. 
The sib pair study 
The design of the European sib pair study with first results from genetic analyses as 
well as the evaluation of the significance of mutations in two genes, UCH~Ll and Par-
kin, in these sib pair families are presented in chapter 4. Up to the end of 1999 a total 
of 246 families with at least two affected siblings were identified and all information has 
been, stored in centralized databases. \,le performed genotyping on three interesting 
regions for PO on chromosome 21', 41' and 4q and observed for one marker D2S1394, 
,8 
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a p-value<O.05 suggesting the presence of a susceptibility region. Mutations in the 
UCH-Ll gene in families with PD \vith an inheritance pattern compatible with autoso-
mal dominant transmission were not found. Different tl1utations in the Parkin gene, 
responsible for an autosomal recessive juvenile parkinsonism (AR-JP) initially described 
in Japan,,) are a common cause for early onset autosomal recessive parkinsonism in 
Europe. However, the phenotype of this subtype of PD in our study was indistinguish-
able from that of idiopathic PD. 
METHODOLOGICAL CONSIDERATIONS 
In this section ,ve will discuss specific methodological issues that pertained to the three 
different approaches of stuoying genetic susceptibility to I'D presenteo in this thesis. 
Familial aggregation study 
A familial aggregation study is generally the first step to provide evidence I"r inheri-
tance of a diseas.e. In fanulial aggregation studie5 the frequency of the same disease in 
relatives of a group of cases with the disease of interest are compared to the frequency 
of the disease in relatives of an appropriate control population. However, fanuly mem-
bers sharing environmental risk factors may explain f,lInilial aggregation. Therefore 
studies on familial aggregation should be interpreted cautiously. Although several stud-
ies have reported familial aggregation of I'D, no prospective population based studies 
on familial aggregation of I'D in the cldedy have been published. These considerations 
were motive to study familial aggregation of PO in the Rotterdam Study. 
Selection bias due to selective lost to follo\v-up is a major threat in prospective 
population based studies. Since lost to follow-up was less than one percent in the Rot-
terdam Study, it is unlikely that this t)1Je of bias has occurred. One might consider that 
if family history 'vere related to early mortality, selection bias might have been intro-
duced because the individual did not live long enough to oevelop PD. Wle did not fino 
an association bel\veen family history and Slllyival suggesting that selective mortality 
did not bias our results. 
Information bias, due to misclassification of disease status of family ll1embcrs, is 
another threat in our aggregation study. A problem in a positive family history is that 
individuals also refer to other diseases like essential tremor or senile tremor and other 
parkinsonian disorders. On the other hand, elderly people arc more likely to loose trade 
of their relatives. Due to the large number of individuaisjt.was not feasible to verify 
family history for each relative and therefore had to rely on self-reported family his tOl,', 
79 
Chaptm !) 
Since this misclassification was most likely to be non-differential it \vill have rtttetmated 
the risk of PD. 
Confounding may have occurred since several environmental risk factors that could 
llumic familial aggregation have been postulated to playa role in PD. Ho\vever, apart 
from sl110king no consistent results have been published. IS Smoking has been reported 
to protect against PD.15 It could be hypothesized that individuals from families with a 
positive Ius tory for PD may smoke less thus increasing their risk of PD. \\le did not 
find evidence for smoking being a confounder in familial aggregation of PD in our 
study. 
Genetic association studies 
Genetic association methods are conceptually straightforward methods to study geneti-
cally determined disease entities. Tn these kind of studies the fre<-Juencies of different 
genotypes and alleles of the candidate gene arc compared bel:\veen individuals with and 
without the outcome of interest In reality, there is quite a number of difficulties. 
Firstly, an appropriate candidate gene has to be found. This may be a gene/protein 
playing a possible role in the pathogenesis of disease, or a gene that is associated with 
other disorders that share dilucal and/or pathological features. However, usually there 
is hardly any solid ground to base the selection of candidate genes on. Secondly, the 
power is often very low. If the etiology of the disease is multifactodal, a true association 
might not be observed. lvloreover, if there is a low increase in the risk, or the frequency 
of the risk allele is lo\v, \ve may lack statistical power. Tn the Rotterdam Study \ve stud-
ied the role of two candidate genes (CYP2D6 and NAT-2) in 80 patients with PD. The 
lowest odds ratio (OR) at a=O.OS and P=0.80 that could be detected would be an 
OR>2, depending on allele frequency and number of controls. TIllS would mean that 
we may have missed a true association if the increased risk of PO for the these genetic 
risk factors is lov,rer than 2. Biological plausibility and initial reports showing an in-
creased risk ofPD Witll ORs>2 fol' botll CYP2D614 and NAT-21J were motive to study 
these gene~ in PD in the Rotterdam Study. Consistent associations bel:\vcen APOE and 
other neurodegenerative diseases like Alzheil1ler'~ diseasc l (, were motive to perfotTI1 a 
candidate gene association study between APO£ and PD. 
Selection bias is likely to occur in candidate gene association studies that are per-
formed in a cross sectional case-control design, like in the studies of chapter 3. Since 
controls were chosen from the same source population from w1uch the cases were de-
rived and individuals from the cohort were exanllned in person, it is not likely that se-
lection bias' may have occurred due to fin ill-defined sampling frame of cont.rols. How-
IJO 
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ever, selection bias may have occurred due to the inclusion of prevalent and incident 
cases in our studies. Based on the assumption that the genetic determinants are not as-
sociated with duration of disease, this mixing should not lead to bias. Ho\vevcr, if the 
genetic polytnorphisms are associated \vith co-morbidity, which may alter disease dura-
tion due to selective survival or change in clinical course, this may lead to bias. The 
prevalent cases in the lnixture may represent a subset of cases that have sutyived long 
enough to be enrolled in the study. This group may be different with respect to risk 
factors, and clinical course, \Yie l1lay partly, solve tius problem by using left truncation 
methods if age at onset can be determined exactly. However, tius is difficult \vith an 
insidious disease like PD. A large case-control study on incident cases, nested within a 
prospective cohort study desigo is probably the most accurate method to avoid this and 
other forms of bias in genetic association studies. In contrast to the NAT-2 and 
CYP2D6 genes, the APOE gene was studied also in incident cases. The results did con-
firnl the overall findings suggesting that the association behveen APOE and PD is true. 
Potential confounders in genetic association studies besides age and gender are ra-
cial and ethnic background. We did not adjust for racial and ethnic background in the 
Rotterdam Study . .i\fost participants are Dutch Caucasian individuals living in tlus area 
for a very long time. Ho\vever, if unmeasured potential confounders introduce differ-
ences in allele frequencies this may lead to spurious results, 
The sib pair study 
It is generally accepted that PO is a genetically complex disease trait in \vhich the mode 
of inheritance is often not clear. The major advantage of the affected sib pair approach 
is that the definition of the nlode of inheritance is not required. The major disadvantage 
of this method is the large number of families required. Another disadvantage we may 
have is that it is likely that parents and even sibs are not alive anymore due to the late 
onset of I'D, which may make it impossible to assess parental haplotypes and handle 
the number of alleles identical by descent. The major problem to overcome in ASP 
studies is genetic heterogeneity. The proportion of ASPs that may be explained due to 
the same gene is determining the po\ver of the ASP study. Strategies to increase homo-
geneity by studying a founder population may increase chances of success. 
Successful applications of mapping genes for complex disease traits17- 1'} in sib pairs 
as well as the availability of more sophisticated statistical methods motivated the estab-
lishment of a consortiU1n to recruit affected sib pairs for a genome wide screen for sus-
ceptibility genes in sib pairs with PD. \\Iith the large set of sib pairs we also have the 
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opportunity to test the significance of published genetic defects responsible for PD or 
subtypes of PD. 
DEFINITION OF OUTCOME 
The generally accepted diagnostic criteria of PD in epidelniological studies l5,2o were 
used within the Rotterdam Study and have heen presented in the introduction of this 
thesis. The diagnostic criteria in the sib pair study were even Inore rigorous, including 
neuropathological diagnosis of PD. H(}\vever, even neuropathological diagnosis may 
bear some misclassification.2 ! In our studies diagnosis of PO was made before the 
genotyping. This minilnizes the probability of introducing misclassification which, if 
any, vvould be non-differential. To minimize misclassification in the Rotterdam Study it 
would be necessary to use more rigorous criteria. However, tills would reduce the 
power of several association studies due to the decrease in the number of definite 
cases.21l To minituize misclassification one might consider a follow-up strategy of the 
affected individuals in which diagnosis of PD may be rejected if initially unidentified 
causes may explain the parkinsonism. This wjJl protect us against false positive diagno-
sis, preventing false negative results, but ,vill lower the power of the study. Another 
advantage is that \ve ,vill have the opportunity to monitor unaffected family members at 
risk of PD. 
Our probability of success would be even higher with the inclusion of multiplex 
families, because we reduce the probability to include nongenetic phenocopies. Ho\v-
ever, such families are relatively rare and again we would reduce the power of the study. 
Definition of the outcome is n difficult problem to overcome since heterogeneity is 
likely to found in a complex disease entity like PD. \,\Ihether all genes responsible for 
PD or parkinsonism represent a spectrum of one clinicopathologic entity or that d1ey 
each reflect a different disease entity is not clear and thus subject of debate. Frotn 
genotype-phenotype correlation studies we know that there are clinical diffcrences be-
twecn the responsible gene and corresponding disease status. However, in many pa-
tients, the phenotype is often indistinguishable from that of idiopathic PD,22 
GENETIC DEFECTS AND PATHOGENETIC MECHANISMS 
The identification of genetic defects responsible for disease may be important in under-
standing the pathogenesis of disease. The natU1'e of mutations in genes associated with 
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PD has been unknown for a long time. The discovery of a mutation in the a-synuclein 
in the Contursi kindred in 19978 has stimulated research in the pathogenetic mecha-
nisms of PD. The availability of a-synuclein antibodies has enabled novel, occult pa-
thology to be described in both neurites in idiopathic PD and other parkinsonian disol'-
ders.2)·24 The presence of Lewy bodies in association with neuronal loss and depigmen-
tation of the substantia nigra is considered the neuropathologic hallmark in PD, albeit 
not totally spedfle. Lewy bodies are also found in other neutodegenerative diseases like 
Le\vy body dementia,25 and Alzheimer's disease.2(1 The a-synuclein protein appeared a 
major component of Lc\vy bodies,2J \vhich accelerated research in Lewy body forma-
tion and deposition. Wfe know that the pathogenic a-synuclein gene mutations are re-
sponsible for a minority of fanillial PO.27 ~{oreover, we know that the wild type (j.-sy-
nuclein is a major component of Lew), bodies in sporadic PD.2l>,2'l This suggests that tbe 
aggregation of the normal u-synuclein protein could be triggered by other 1nechanisms. 
For example, damage to the protein3!))1 or abnormal catabolism:\2 may lead to an ab-
normal aggregation. Synuclein abnormalities are also found in other interesting parkin-
sonian disorders like multiple system atrophy (MSA)21 and amyotrophic lateral sclerosis 
(ALS)." Moreover, it has been shown that axon pathology in PO and Lewy Body de-
mentia hippocampus contains U-, f3-, and y-synuclein.·B This provides even 1110re evi-
dence that synuclein pathology is playing a role in PD and other neurodegenerative dis-
eases. 
Another mutation, responsible for familial PD, \vas found in the UCH-Ll gene. 
Like the a-synuclein gene product, the UCH-Ll protein is a constituent of Lewy bod-
ies." UCH-LJ is thought to playa role in the cleavage of polymeric ubiquitin into 
monomers and may as well hydrolyze C-tcrminal esters and 'amides of ubiqnitin;15 The 
malfunctioning of the ubiquitin-dependent proteolytic system is known to be involved 
in the formation of intrancuronal inclusion bodiesY,,37 Recently it has been sho\vn that 
the a-synuclein protein is det,rraded by the ubiquitin-proteasome protcolyic pathway.·u 
TIllS suggests that malfunctioning of tllls system may be involved in the etiology of PD. 
Finally, the si1nilarity of the Parkin protein,) to the ubiquitin protein family strength-
ens the hypothesis tl,at the ubiquitin-dependcnt proteolytic system may playa role in 
the pathogenesis of PD. However, the lack of Le,,~' bodies in AR-JP suggests that 
other factors in neurodegeneration like oxidative stress·1l and specific neurotoxinsJ::) JI) 
may be involved in the pathogenesis of PD. 
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RECOMMENDATION FOR FUTURE ETIOLOGICAL RESEARCH 
The genes or loci described so far in PO are responsible for only a minority of PO 
cases. W/e have to consider that the cause of PO is likely to be multifactorial, in \vhich 
two or more genes together vlith environmental effects may lead to the phenotype(s) of 
PO during life. If there is some biologic plausibility for interaction, it might be worth-
while studying these kind of interactions. Since these possibilities arc so diverse, any 
genetic association study, prone to interaction with odler genetic 01' environmental 
factors, is subject of debate and results should be interpreted cautiously. To disentangle 
these interactions we first have to iuentify the genetic risk factors since these factors are 
usually stable during life. Once genetic risk factors are identified the study of interaction 
will become more feasible. Different methods can be used to identify other genetic risk 
factors in PD. 
j\Iajor genes are more likely to be found in large families or in genetic isolates. 
Large families are rare anu a 1najor gene responsible for PD in that family may be spe-
cific and not generalizible to other families. Ho\vever, we may obtain more insight in 
the pathogenetic mechanisms of PD. 
The advantage of mapping genes in genetic isolates is that a limited nunlber of 
genes with a limited number of ll1utations may be responsible for PD or subtypes of 
PO. This reduces the complexity of genetic heterogeneity and the probability of finding 
a gene responsible for PO will be higher. 
Recently a twin study showed that heritability plays a role in early onset PO'''. We 
therefore may increase our chances to find a gene, if we focus on early onset PD. How-
ever, the findings presented in this thesis suggest that genetic factors also playa role in 
the elderly. 
As discussed previously the affected sib pair method is a good approach to identify 
susceptibility genes in PD. Since this method has been successful in other complex 
traits,17-19 it will be worthwhile to collect as much as possible affected sib pairs. Up to 
present five European countries have participated in the collection of affected sib pairs. 
It is \varranted to expand tlus project both on national and international level. \\lith the 
increasing number of DNA-markers and rapid improvements .in molecular genotyping, 
the (fishing expedition', often used by epidemiologists in classical case-control studies 
will aid the identification of susceptibility genes in po. 
The role of tlle candidate gene association study in identifying genetic risk factors 
of a heterogeneous disease like PD is subject of debate. The study design is often sus-
ceptible to several forms of bias. This does not imply that these kind of studies are not 
important in the studying genetic factors in po. \\Ihen dlere is biological plausibility 
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and the sample size is large enough it can be extremely worthwhile performing these 
studies. It is important that cases and controls are sampled from the same source 
population in which there is no population admixture. The results should be repro-
duced in other independent datasets with similar study design. 
lvIoreover in genetically complex diseases entities candidate gene association studies 
can play an important role in the tIne mapping of regions once susceptibility regions 
have been found in linkage studies. Once novel genetic defects have been identified, 
it will be important to assess its relevance in a general population. Existing datasets, 
on population level, like the Rotterdam Study, will be extremely \vortll\vhile to test the 
signiHcance of these identified genetic defects in PD. 
Not only the identification of novel genes, but also the search for otiler 
genes/proteins that aught be associated with the genes already known as PD-genes may 
be of interest and could be analyzed in the affected sib pail' study or the Rotterdam 
Study. An excellent example is the structural similarity of the apolipoprotein-E to the 
u-synuclein and tile increased susceptibility to sporadic PD by a certain combined u-
synuclein/ apolipoprotein-E genotype."' The availability of the sequence of the entire 
human genome (HUGO) by the year 2002 will be of major help in the search of candi-
date genes and genes \vith homology to the yet identified PD genes. Finally we may 
perform genotype-phenotype correlation studies. \,\Iith the identification of other genes 
we may classify I'D or subtypes of PD. 
Current thinking is that the etiolot,lJr of PD is nlultifactorial and that several suscep-
tibility genes and environmental factors may be involved. The genes and loci described 
so far in I'D are responsible for a minority of I'D patients. It is likely that other genetic 
risk factors for PO may be discovered shortly. A challenge will then be to find out 
whether such genes act in isolation or in interaction with other genes or envirollinental 
risk factors in hringing out the disease. Studies on the function of the genes that have 
been identified will help in understanding the pathophysiology of I'D but may also help 
direct future etiologic research. The better we understand the causes of PD, the closer 
we may get to the ultimate aim of prevention of this common disabling disorder. 
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SUMl\1ARY 
P AIUGNSON'S DISEASE (PD) is a common neurodegencrative disorder among the '.. .. e1dcrly, and a major health problem due to its disabling character. Clinically, PO is characterized by resting tren1ot, bradykinesia, rigidity and postural distur-
bances. The cause of PD is still largely unknown and treatment is symptomatic with 
only temporary results. Studies on families with PO have clearly indicated that genetic 
factors may playa role in PD. Since 1997, mutations in three genes, a-synudein, UCH-
Ll, and Parkin have been identificd as causes of PD. lvforeover two loci (2p 13 and 
4p14-16.3) have been found that are associated with PD. These observations provide 
convincing evidence that PO is a genetically heterogeneous disorder. 
The objective of the work presented in this thesis was to study genetic susceptibility 
to PD. We did this in two diffcrent studies, the Rotterdam Study, which is a prospective 
population-based cohort study on frequency, etiology and prognosis of chronic diseases 
among 7983 individuals aged 55 years and over, in Ommoord a suburb of Rotterdam, 
and in a large European collaborative sib pair study on PD. We used different methods 
to study the significance of genetic factors in PD. Firstly, as presented in chapter 2, we 
analyzed whetller there was familial aggregation of PO in the Rotterdam Study. Sec-
ondly, wc performed gcnetic association studies to study candidate genes in PO (chap-
ter 3). Finally, linkage studies and genetic association studies in affected sib pairs were 
used to study genetic susceptibility to PO (chapter 4). All studies werc approvcd by the 
Medical Ethical Committee of thc Erasmus Medical Center Rotterdam and all partici-
pants gave their infonned consent according to the Declaration of Helsinki. 
In chaptet· 2.1, we describe the association between family history of PO and the 
risk of PO in the elderly population of tl,C Rotterdam Study. To datc, no prospective 
population based studies on familial aggregation of PO have been published. We found 
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that individuals with a first degree relative with PO had a 50'10 incrc",ed risk to develop 
PO as conlpared to those without such a family history. For subjects \vith at least two 
Hrst degree relatives \vith PD the 1'isk was more than fivefold increased. These observa-
tions suggest that genetic factors may playa role in the occurrence of PD in the elderly. 
Next, we studied the association bet\veen three candidate genes and PO \vitlun the 
Rotterdam Study (chapter 3). The first two candidate genes, N-aeetyltransferase-2 
(NAT-2) and cytochrome P-450 debrisoquine hydroxylase (Cl'P206) arc thought to be 
involved in the metabolism of neurotoxins and have been associatec.l with PD. The 
third candidate gene, apolipoprotcin-E (APOE), is as far as known, not involved in the 
nletabolisnl of neurotoxins but has been associated \vith other neurodegenerative dis-
eases including Alzheimer's disease and Lewy body disease. 
In chapter 3.1 we evaluated the role of the NAT-2 gene in PD. The genotype re-
sponsible for slow acetylation was previously reported to be increased in PD patients. 
Slow acetylators are homozygous for any of the mutant alleles and may be more sus-
ceptible to low-level environmental exposure to neurotoxins. The finding of an in-
crcased frequency of subjects homozygous for the NAT -2 gene mutations would have 
been compatible with the view that PO patients mal' be less capable to handle certain 
endogenous or exogenous toxins. \Y,/e investigated three mutant alleles, 1H, 1\·12 and 1\-13 
and the wild type allele of the NAT-2 gene in 80 patients with idiopathic PO and 161 
age matched randomly selected control subjects from the Rotterdam Study. The allelic 
frequencies and genotype distributions were very sinillar in cases and controls. Interest-
ingly, in controls the frequency of the wild type allele increased significantly with age 
suggestit1g that dle 111utant alleles may be associated with an increased risk of nlortality 
(ptr,"d<O.OOI). We concluded that the NAT-2 gene is not a major genetic determinant 
of PO, but may be a determinant of mortality in the general population. 
In chapter 3.2 the association between the CYP206 gene and PO is described. 
The C)'P206 gene is known to be involved in the metabolism of the neurotoxin 
:i\{PTP, which has been shown to inc.luce parkinsonism in humans. The initial repotts 
on the C,'P206 gene and PO described that poor metabolizers homozygous for any 
mutant allele had an increased risk of PD. Later studics, in odler populations, have tried 
to confirm the initial findings but with conllicting results. Several explanations, like dif-
ferences in study design or bias in the selection of the control population have been of-
fered for this. The Rotterdam Study provided the possibility to assess ti,e significance 
of the C)'P206 gene in PD in a case-control study in \"hleh cases and controls were 
sampled from the same source population. \"\Te investigated two mutant alleles, 
C,'P206*3 and Cl'P206*4, both associated with poor metabolism, and the wild type 
allele in 80 patients Witll PO and 156 control subjects, frequeney matched on age and 
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gender. No differences behveen cases and controls were found for the poor me-
tabolizer genotype. Our results suggest that the CYP2D6 gene is not a major determi-
nant of PD. 
In chapter 3.3 we report the association between the APOE genotype and PD. 
The apolipoprotcin 84-allele is assodated with Alzheimer's disease and Lewy Body dis-
ease. Reports on APOE genotype and PO are not consistent. We therefore studied the 
risk of PO with or without dementia as a function of APOE genotype. APOR geno-
typing was available for 107 PO patients (26 with and 81 without dementia) and 4805 
non-parkinsonian controls. Individuals with at least one 82-allele \vete almost twice as 
likely to have PD as compared to individuals with the most frequent genotype 
APOE3E3. When we looked separately for demented and non-demented PO patients 
as compared to non-parkinsonian controls, APOE genotype appeared not associated 
with PD without dementia, but carriers of the c:4-allele and the 82-allele had a four to 
five times increased risk of PD with dementia. For carriers of an c:4-allele the risk of 
dementia was sitnilarly increased in non-PD and PD subjects, ho\vevcr, for carders of 
an c:2-alle1e the increased risk of dementia was confined to PO patients. \X1hen \ve pro-
spectively studied the risk of dementia in non-demented PO patients we found that 82-
allele carriers had a more than '10 times higher risk of dementia as compared to c:3c:3 
subjects. These findings suggest that in the elderly the APOE 82-allele increases the risk 
of PO and in particular the risk of PO with dementia. 
Chaptet· 4 is devoted to the analysis of susceptibility genes in European affected 
sib pairs with PD. \Ve established a European Consortium on Genetic Susceptibility to 
PO (GSPD) with the objective to study known and other, not yet identified, suscepti-
bility genes in affected sib pairs with PD. In tlus chapter ti,e design of the European sib 
pair study is presented as well as the evaluation of the significance of kno\vn mutations 
in two genes, UCH-Ll and Parkin, in these sib pairs. 
In chaptet· 4.1 we present the sib pair study design and the results from genetic 
analyses on three interesting chromosomal regions in PD. The GSPD-study started in 
1995 "'lith the recruitment of families with PO and \vas conducted in five European 
countries. Different established links and communication nehvorks were used to iden-
tify families with at least 1'.vo affected sibs with PD using rigorous diagnostic cdteria. 
All the affected family members were personally examined, videotaped and blood sam-
ples \vete taken using a standardized protocol. In order to detern1ine allele segregation 
in the fanlilies, we collected blood from parents and unaffected siblings if available. Up 
to the end of 1999 a total of 246 fanlilies with at least two affected siblings from five 
countries ,were, identified and all information had been' stored, in centralized' databases. 
Chapter f:i.·l 
\,\Ie performed genotyping in 125 highly informative families with affected sib pairs on 
three interesting regions for I'D on chtomosome 2p and 4p and 4q using 12 DNA-
markers. For one marker D2S1394, we observed a nominal p-value of 0.05 or lowel" 
suggesting the presence of a susceptibility region. 
In chapter 4.2 we present our assessment of mutations in the UCH-Ll gene in the 
sib pair study. A German group had reported a mutation in the UCH-Ll gene, respon-
sible for PO \vith an inheritance pattern compatible \'lith autosomal dominant transmis-
sion in a German sibling pair. The mutation in this gene is responsible for an impaired 
ptoteolytic activity of the UCH-Ll protein and ma), lead to an abnormal aggregation of 
proteins in the brain. In order to determine the importance of this or any other muta-
tion in the coding region of the UCH-Ll gene in I'D, we performed mutation anal),sis 
on the complete cocling region of the UCH-Ll gene among 96 Caucasian affected sib 
pair families. \Yie did not detect any mutations in the UCH-Ll gene, ho\vever, \ve could 
not exclude mutations in the regulatory or intronic regions of the UCH-Lt gene since 
these regions were not sequenced. \\le concluded that mutations in the UCH-L1 gene 
are a rare cause of familial PD. 
In chapter 4.3 we studied the Parkin gene, which was initially described in Japan 
where it was found to be responsible for autosomal recessive juvenile parkinsonism 
(AR-Jp). Several mutations in this gene have been described since. We have analy%ed 
the t2 coding exons of the Parkin gene in 35 families, mostly European, \vith early on-
set autosomal recessive parkinsonism. This study has sho\vn that a wide range of differ-
ent tl1utations in the Parkin gene are a common cause for early onset autosotnal reces-
sive parkinsonism in Europe, and that point mutations of various types are more frc-
quently responsible for the clisease phenotype than deletions are. IvIean age at onset was 
38±12 years, but onset up to age 58 was observed, showing that mutations in the Par-
kin gene were not invariably associated \vith early onset parkinsonism defined as an 
onset of younger than 45 years. In nlany patients, tlle phenotype \vas indistinguishable 
ftom tl,at of icliopathic PD. 
In chapter 5.1 the finclings presented in this thesis were placed in a broader per-
spective, as \vere issucs relating to shldy design. \Vie discussed some mcchanisms that 
may potentially underl), I'D and reflected on the clinical and scientific impact of our 
and other genetic stuclies in PD. 
Current thinking is that the etiology of I'D is multifactorial and tl,at several suscep-
tibility genes and environmental factors may be involved. TI,e genes and loci described 
so far in I'D arc responsible for a minority of I'D patients. It is likely that otl,er genetic 
risk factors for I'D may be discovered shortly. A challenge will then be to find out 
whether 'such genes act in isolation or in interaction with other genes or environmental 
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risk factors in bringing out cile disease. Studies on the function of the genes that have 
been identified will help in understanding the pathophysiology of I'D but may also help 
direct future etiologic research. The better we understand the causes of PO, the closer 
\ve may get to the ulthnatc ainl of prevention of this common disabling disorder. 
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SANIENVA ITING 
DE ZIEKTE VAN Parkinson is cen frctjuent voorkomcnde ncurodcgcneraticve : ,i aandoening onder ouderen en yormt door haar invalidercnde karakter cell be-langrijk gezondheidsproblcem. Klinisch wordt de ziekte van Parkinson geken-
merkt door rusttremor, bradylcincsic, rigicliteit en gcstoorde houdingsreflexcn, De 001'-
zaak van de :,dekte van Parkinson is nog steeds grotendcels onbekend en de behandeling 
is symptomatisch met aileen tijdelijk resultaat. 
Studies in families met de zickte van Parkinson hebhcn aangetoond dat genetische 
factoren mogelijk een 1'01 spelen bij de ziekte van Parkinson. Vanaf 1997 zijn in drie ge-
nen, a-synudein, UCH-LI en Parkin, mutaties gddentificeerd die de zickte van Parkin-
son veroorzaken. Daarnaast zijn twee loci (2p13 en 4pI4-16.3) gevonden die geasso-
cicerd zijn met de ~dekte van Parkinson. Dcze bcvindingen lcveren overtuigend bewijs 
dat de ziekte van Parkinson cen gcnetisch hetcrogene aandoening is. 
De doelstclilng van het werk beschreven in dit proefschrift was het bcstuderen van 
de geneti,che gevoeligheid bij de ziekte van Parkinson. We hebben dit gedaan in twee 
verschillende studie" het Erasmus Rotterdam Gezondheid en Ouderen (ERGO) 
onderzoek - in het Engels Hthe Rotterdam Study" - ecn prospectief bevolkings-
onderzock naar frequentie, oorzaak en prognose van chronische aandoeningen onder 
7983 inwoncrs van 55 jaar en ouder in de \vijk Ommoord .in Rotterdam, en in een groot 
samenwerkend Europees sibparen-ondcrzoek (paren van broers en/of zllsters Inet de 
ziekte van Parkinson). We hebben versehillende methoden gebruikt om de significantie 
van genetische factorcn bij de ziekte van Parkinson te bcstudcren. Ten ecfste - zoals 
beschreven in hoofdshlk 2 - hebben we onderzacht of er familieaggregatie bestand bij 
de ziekte van Parkinson binnen de ERGO-stuclie. Ten tweedc deden we gene tisch 
assodaticonderzoek om kandidaat-genen bi) de ziekte van Parkinson te bestudcren 
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(hoofdstuk 3). Ten slotte hebben we gebruik gemaakt van linkage studies en genetisch 
associatieondcrzoek om genetische gevoeligheid bij de ziekte van Parkinson te bestude-
ten in aangedane sibparen. Aile studies werden goedgekeurd door de Medisch Ethisehe 
Con1missie van de Erasmus Universitcit en aBe dec1nemers hebben toestemming, 
gebaseerd op het verdrag van Helsinki, verlcend voor het verrichten van het onderzoek. 
In hoofdstuk 2.1 bcschrijven we het verband tussen fatniliegeschiedenis van de 
ziekte van Parkinson en de kans op de ziekte van Parkinson bij ouderen in het ERGO-
ondcrzoek. Tot op heden is er geen prospcctief bevolkingsonderzoek over familieaggre-
gatie bij de ziekte van Parkinson gepubliceel'd. \Y.Te vonden dat personen met ten minste 
een eerstegraads familielid met de ziekte van Parkinson 50% meer kans hadden op het 
krijgcn van de ziekte van Parkinson dan pcrsonen zonder familicleden mct deze aan-
doening. Eij personen met ten minste twee cerstegraads familicleden met de ziekte van 
Parkinson was dit risico meet dan vljf keel' verhoogd. Deze bevindingen geven aan dat 
erfelijke factoren mogelijk ecn 1'01 spelcn bij het ontstaan van de ziekte van Parkinson. 
VenTolgens beshldeerden ,ve de associatie tussen dde kandidaat-genen en de ziekte 
van Parkinson binnen de ERGO-studie (hoofdstuk 3). De eerste twee kandidaat-
genen, N-acetyltransferase-2 (NAT-2) en het eytoehroom P450 debrisoquine hydroxy-
lase (CYP2D6), zijn mogelijk betrokken bij het metabolisme van neurotoxines en wer-
den geassocieerd met de ziekte van Parkinson. Het derde kandidaat-gen, apolipopro-
tcine-E (APOE), is vool' zover bekend niet betl'okken bij het metabolisme van neuro-
toxinen, maar werd gcassocieerd met andere neul'odegcneratievc aandoeningen, inclu-
sief de ziekte van Alzheimer. 
In hoofdstuk 3.1 evalueerden we de 1'01 van het NAT-2 gen bij de ziekte van 
Parkinson. Bet genotype verantwoordelijk voor lang7.ame acetylering werd in het vcr-
leden in cen verhoogde frequentie gevonden bij patientcn met dc ziekte van Parkinson. 
Langzame acetyleerders zijn homozygoot voor gemuteerde aJlclen en kunnen cen ver-
hoogde gevoeligheid vertonen voor expositic aan bepaalde neurotoxines. De bevinding 
van een verhoogde frequentie van het genotype h01110Zygoot voor het gemutcerde allel 
zo1..1 verenigbaat zijn met de hypothesc dat mensen met de ziekte van Parkinson slechter 
in staat zijn bepaalde exogene en endogene ne1..1rotoxines tc vet\verken. \\Te hebben ge-
keken naar drie gem1..1teerde aUelen 1\H, Ivf2 en 1\,13 en het norm ale, meest voorkomende 
allel van het NAT-2-gen in 80 patienten met de ziekte van Parkinson en 161 ascleete 
contro1epersonen uit het ERGO-onderzoek met dezclfde leeftijd. De verdeling van de 
allclen en genotype in patientcn wa::; vcrgelijkbaar met die van de controlepersonen. 
Een interessante bevinding 'vas dat de frequentie van het nonnale ailel toenam met de 
lceftijd (Ptrend<O.OOI) waardoor een associatie tussen gemuteerde allelcn en verhoogd 
risieo op sterfte wordt gesuggereerd. We concludercn dat het NAT-2-gen geen belang-
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rijke dcterminant is hij de ziekte van Parkinson, maar mogelijk een determinant zo1.1 
kunnen zijn van sterfte in de algemene populatie. 
In hoofdstuk 3.2 wordt het verband tussen het CYP2D6-gen en de ziekte van 
Parkinson besehreven. Van het CYP2D6-gen is bekend dat dit gen betrokken is bij het 
metabolisme van het neurotoxine n'fPTP, waarvan is aangctoond dat het parkinsonisme 
veroorzaakt. De initiele studie naar het CYP2D6-gen bij de ziekte van Parkinson be-
schreef dat slechte metaboliseerdcrs, homozygoot voor gemutcerde allelen, cen vcr-
hoogd risico hadden op de ziekte van Parkinson. In latere studies in andere populaties 
is gcprobcerd de res1.1ltaten te rcproduceren, echter zander consistente resultaten. Hier-
voor wordt een aantal verklaringen, zoais verschillen in studieop7.et en vertekcning van 
de associatie door selectic van de controlepe1'sonen, gepostuleerd. De ERGO-studie 
versehafte de mogelijkheid deze assodatie te bestuderen in een patient/ eontrole-onder-
zoek \vaadn de patientcn en controlepersonen werden gesclecteerd uit dezelfde onder-
zoekspopulatie. \'(Ie hebben gekeken naar twee gemuteerde aUden en het normale, 
meest voorkomende allel, in 80 patienten met de ziekte van Parkinson en 156 aselecte 
eontrolepersonen uit het ERGO-onderzoek met dezelfde leeftijdsverdeling als bij de 
patientcn. E1' werden geen verschillen tussen patientcn en conttolepersonen gevondcn 
voor het genotype veranhvoordelijk voor slechte metabol1sering. Onze resultaten sug-
gereren dat het CYl'2D6-gen geen belangrijke determinant is bij de ziekte van Parkin-
son. 
In hoofdstuk 3.3 rapporteren we de assaeiatie tussen APOE genotype en de ziekte 
van Parkinson. Het apolipaproteine 84-aUe! is geassocieerd met de ziekte van Alzhei-
mer en de Lewy body ziekte. Studies over het APOE gen bij de ziekte van Parkinson 
zijn niet consistent. Dam'om bestudecrden wi; de kans op dc 7.iekte van Parkinson, met 
of zander dementie, als funetie van het APOE genotype. APOE gentypering was be-
sehikbaar voor 107 patienten met de ziekte van Parkinson (26 met en 81 zonder de-
mentie) en 4805 controlepersonen zondcr parkinsonisme. Personen met ten minste een 
82-allel hadden een bijna twee keer verhoogd risico 01' het krijgen van de ziekte van 
Parkinson vergeleken met personen met het meest frequente genotype APOE3E3. 
lndien we apart keken naar demente en met den1ente patienten met de ziekte van 
Parkinson vonden we geen associatie met de ziekte van Parkinson :londer den1entie, 
maar dragers van zowe! het 82-allel als het 84-aUel hadden een vier- tot vijfvoudig ver-
hoogd risico 01' de ziekte van Parkinson met dementie. VOO1' dragers van het 84-allel 
was de kans op delnentie niet significant verschillend voor personen met of zonder de 
ziekte van Parkinson, maar Vaal' dragcrs van het e2-alIe1 \vas het risico van denlentie 
aUeen verhoogd bij patienten met de ziekte van Parkinson. Indien we prospeetief keken 
naar de kans op dementie bij met demente patienten met de ziekte van Parkinson, von-
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den \ve cIat dragers van het e2-ailel cen meer dan tienvoudig verhoogd risico hudden op 
dementie vergcleken met bet APOE3E3-genotype. Deze bevindingen suggereren dat 
het APOE-s2-aUel bij ouderen het risico voor de ziekte van Parkinson, in het bijzonder 
de ziekte van Parkinson met dementie, verhoogt. 
Hoofds!uk 4 is gewijd aan de analyse van gevoeligheidsgenen in Europese sibparen 
met de ziekte van Parkinson. \"Xlij rlchtten een Europees consortium aangaande de gene-
tisehe suseeptibiliteit voor de ziekte van Parkinson (GSPD) op, met als doelstclling be-
kende en onbekende, nag niet getdentificeerde, gevoeligheidsgenen te bestuderen in 
aangedane sibparen. In dit hoofdstllk ·worden het ont\verp van deze studie alsmede de 
evaluatie van de significantie van bekende mutaties in twee genen, UCH-Ll en Parkin, 
in aangedane sibpaten gepresenteerd. 
In hoofdstuk 4.1 bcschrijven we de opzet van de sibparenstudie en presenteren we 
resultaten vall drie interessante chromosomale loci bij de ziekte van Parkinson. De 
GSPD-studie startte in 1995 met de werving van families met de ziekte van Parkinson, 
uitgevoerd in vijf El.lropesc landen. Verschillende links en communicatienet\verken 
\verden gebruikt om families met ten minste t\vee aangedane broets en of zusters met 
de ziekte van Parkinson te identificeren met gebruikmaking van zeer strikte diagnosti-
sche criteria. Aile aangedane familieleden werden persoonlijk onderzocht, gefiltnd en bij 
aile deelnemers werd bloed a(genomen volgens een gestandaardiseetd protocol. Om de 
ailel segregatie vast te steilen werd, indien beschikbaar, bloed afgenomen bij Duders en 
niet aangedane broers en of zusters. Tot eind 1999 hebben we in totaal 246 families met 
ten minstc t\vee aangedane broers en of zusters ge'identificeerd en aile gegevens zijn 
opgeslagen in centrale databestanden. In 125 zeer infonnatieve families met ten minste 
t\vee aangedane broers en/of zusters hebben \ve gezocht naar predlsponerende gebie-
den met bebulp van 12 markers 01' chrotnosoom 21' en 41' and 4q, gebruikmakend van 
t\vopoint en multipoint aangedane sibparen analyses. Voor cen marker, D2S1394, von-
den \ve een l10minale p-\vaarde klciner dan 0.05 waardoor de aanwezigheid van cen 
genetisch suspect gebied \vordt gesuggereerd. 
In hoofstllk 4.2 bcschrijven we het onderzoek Haar mutatics in het UCH-L1-gen in 
de sibparen. Ben Duitse groep rapporteerde in cell Duitse familie een mutatie in het 
UCH-Ll-gen, verant\voordclijk voor de ziektc van Parkinson met cen overervingspa-
troon compatibel met autosomaal dominante transmissie. Dc 111utatie in dit gen is 
vcrantwoordelijk voar een verminderdc protcolytische activitcit van het UCH-L1-eiwit, 
mogelijk leidend tot een abnorma1c aggtcgatie van ciwitten in de hcrsenen. Om de 
significantie van deze en/of andere mutatics in coderende gebieden van dit gen te 
bestuderen, hebben we mutaticanalyses uitgevocrd bij 96 Kaukasischc sibparenfumilies. 
"(ie hebben gcen ll1utaties in het UCH-Ll-gen gevonden, alhoewel we mutaties in' de 
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niet coderende gebieden niet konden uitsluiten, daar deze gebieden niet werden geana-
lyseerd. We concluderen dat het UCH-Ll-gen een zeldzame oorzaak is voor de familiai-
re ziekte van Parkinson. 
In hoofdstuk 4.3 presenteren we het Parkin gen, voor het eerst beschreven in 
Japan, waar het verantwoordclijk bleek te zijn voor autosomaal reccssief juveniel par-
kinsonisme (AR-JP). \\le hebben de 12 eoderende gebieden op dit Parkin gen onder-
zocht in 35 families, de ll1eeste van Europese origine, met een op vroege leeftijd 
beginnend parkinsonisme. Deze studie laat zien dat cen brede variatie aan mutaties in 
het Parkin gen een algemene oorzaak is van autosomaal recessief parkinsonisme in 
Europa en dat puntmutaties vaker veranhvoordelijk blijken voor het fenotype van de 
ziekte dan ddeties. De gemiddclJe leeftijd waarop de ziekte begon was 38±12 jaar, maar 
ecn beginleeftijd van 58 jaar werd ook waargenol11en. De ziekte lijkt hierdoor dus niet 
beperkt tot een vroege aanzet Bovendien blcek bij vecl patienten de zickte niet te 
ondcrscheiden van de idiopatische ziektc van Parkinson. 
In hoofdsluk 5.1 worden de resultaten, beschreven in dit proefsehrift, geplaatst in 
cen breder perspectief, evenals opmerkingen aangaande studieopzet. \Xfe bespreken 
sommige mechallismcn die 1110gclijk onderliggend zijn aan de ziekte van Parkinson, 
gereflecteerd aan klinische en wetenschappelijke impact van onze en andere studies aan-
gaande de ziekte van Parkinson. 
Het is algemeen aanvaard dat de oonaak van de ziekte van Parkinson multi-
factorieel is, waarbij verschillende gevoeligheidsgenen en omgevingsfactoren tllogelijk 
betrokken zijn. De tot dusver beschreven gencn en loci zijn veranhvoordclijk voor 
slechts cen kleine groep van patienten met de ziekte van Parkinson. Het is waarschijn-
lijk dat andere genctische ris1cofactoren binnenkort zullcn worden ontdekt. Een 
uitdaging zal dan zijn 0111 tc ooderzoekcn of deze genen aileen of in interactie l11et 
andere genen en/of omgevingsfactoren leiden tot de ziekte. Studies oaar de functie van 
deze geidentificeerde genen zullen bijdragen aan het bcgrijpen van de pathof),siologie 
van de ziekte van Parkinson, maar oak toekotnstig etiologisch onderzoek initieren. Hoe 
beter \ve de oOfzaak van de ziekte van Parkinson begrijpen, des te dichter \ve :lullcn 
k01nen bij het ultiel11c doel, de prevcntie van dcze invaliderendc aandoening. 
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